Technologies for Proteomic and Genomic Biomarker Analysis by Liu, Yiding
Cleveland State University
EngagedScholarship@CSU
ETD Archive
2008
Technologies for Proteomic and Genomic
Biomarker Analysis
Yiding Liu
Cleveland State University
Follow this and additional works at: https://engagedscholarship.csuohio.edu/etdarchive
Part of the Chemistry Commons
How does access to this work benefit you? Let us know!
This Dissertation is brought to you for free and open access by EngagedScholarship@CSU. It has been accepted for inclusion in ETD Archive by an
authorized administrator of EngagedScholarship@CSU. For more information, please contact library.es@csuohio.edu.
Recommended Citation
Liu, Yiding, "Technologies for Proteomic and Genomic Biomarker Analysis" (2008). ETD Archive. 187.
https://engagedscholarship.csuohio.edu/etdarchive/187
  
 
TECHNOLOGIES FOR PROTEOMIC AND GENOMIC 
BIOMARKER ANALYSIS 
 
YIDING LIU 
 
BACHELOR OF SCIENCE IN CHEMISTRY 
ZHENGZHOU UNIVERSITY 
ZHENZHOU, HENAN PROVINCE, P.R.CHINA 
SEPTEMBER 1999 
 
 
submitted in partial fulfillment of requirements for the degree 
DOCTOR OF PHILOSOPHY IN CLINICAL-BIOANALYTICAL CHEMISTRY 
at the 
CLEVELAND STATE UNIVERSITY 
DECEMBER 2008 
 
 
This dissertation has been approved 
for the Department of CHEMISTRY 
and the College of Graduate Studies by 
 
_________________________________________ 
Dissertation Chairperson, Baochuan Guo 
Department of CHEMISTRY 
________________________ 
Date 
 
_________________________________________ 
Lily M Ng 
Department of CHEMISTRY 
________________________ 
Date 
 
_________________________________________ 
Crystal M. Weyman 
Department of BIOLOGICAL, GEOLOGICAL, and ENVIRONMENTAL SCIENCES 
________________________ 
Date 
 
_________________________________________ 
Aimin Zhou 
Department of CHEMISTRY 
________________________ 
Date 
 
_________________________________________ 
Xiang Zhou 
Department of CHEMISTRY 
________________________ 
Date 
 ii
TECHNOLOGIES FOR PROTEOMIC AND GENOMIC BIOMARKER 
ANALYSIS 
YIDING LIU 
ABSTRACT 
In the first part of this dissertation, we systematically validated the application of 
molecular weight cut-off ultrafiltration in separation and enrichment of 
low-molecular-weight peptides from human serum. Under optimized conditions, both 
free-phase and bound LMW peptides could be separated and enriched. The method 
proved to be highly efficient and reproducible coupled with MALDI-TOF MS proteomic 
pattern analysis. Three marker peaks were found to be eligible for distinguishing normal 
and ovarian cancer samples. 
A novel organic solvent precipitation method coupled with enzymatic 
deglycosylation was also developed for biomarker detection from human serum. This 
method allowed us to generate reproducible free-phase peptide patterns comparing with 
the ultrafiltration method. A potential marker was found up-regulated in benign and 
ovarian cancer patients. It was further identified as des-alanine-fibrinopeptide A using LC 
tandem mass spectrometry.  
In the second part of this dissertation, a new sample preparation procedure was 
developed to improve the MALDI-TOF analysis of low-concentration oligonucleotides. 
The oligonucleotide solutions are first dispensed and allow shrinking onto a small spot on 
an anchoring target. A small volume (0.1uL) of saturated 3-HPA matrix solution is then 
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added on top of each dried oligonucleotide spot. Samples prepared by this procedure are 
homogenous and reduces the need to search for ‘sweet’ spots. The increased shot-to-shot 
and sample-to-sample reproducibility makes it useful for high-throughput quantitative 
analysis. This procedure allowed robust detection of oligonucleotides at 0.01µM level and 
mini-sequencing products produced using only 50 fmol of extension primer. 
And a strategy called probe-clamping-primer-extension-PCR (PCPE-PCR) was 
developed to detect MRS alterations in a large background of wild-type DNA. PCR 
errors often generate false positive mutant alleles. In PCPE-PCR, mutant single-strand 
DNA molecules are preferentially produced and enriched. Thereafter, the remaining 
single-strand mutant DNA molecules were amplified using PCR and analyzed to reveal 
the MSI-H status. We showed that PCPE-PCR could detect both mutated BAT26 and 
TGF-h-RII(A)10 markers in the presence of 500-fold excess of normal DNA and that as 
few as three copies of mutated DNA could be detected. We also showed that this 
technology could detect MSI-H colorectal cancer by fecal DNA analysis. 
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PART I 
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CHAPTER I 
GENERAL INTRODUCTION 
 
 
 
1.1 Proteomics Basics 
After the human genome sequence was determined in 2000, molecular 
medicine research moved further beyond genomics to proteomics.  
What is proteomics? Although the exact definition of proteomics evolves 
along with research progress [Wasinger et al., 1995; Loo et al., 1996; Wilkins et al., 
1996; Hochstrasser, 1998], it is widely accepted now that proteomics is “the study of 
all the protein forms expressed within an organism as a function of time, age, state, 
external factors, etc.” [Reynolds, 2002]. In other words, the types of expressed 
proteins, their abundance, state of modification, sub-cellular location, etc. are 
dependent on the physiological state of the cell or tissue. Therefore, proteomic 
analysis can be considered as an assay surveying throughout the whole genome to 
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differentiate and study cellular states and to determine the molecular mechanisms 
behind them [Haynes et al., 1998]. 
Why proteomics? After the Human Genome Project was completed, 
researchers noted that the genomic information itself can not accurately predict what 
is actually occurring at the protein level within a certain cell type. The expression of 
genes in a specific cell is affected by numerous factors as a result of tissue complexity, 
inter- or intracellular signaling and responding to changes in their environment. Since 
proteins are the working units to perform functions of a cell, and since their 
expression, structure, and activity can be changed any time through post translational 
modifications, proteomics, a new paradigm comparable to genomics, is therefore 
needed. Proteomics provided a powerful approach for differentiating normal and 
transformed cell formations, identification of molecular targets from complex 
mixtures which are specific to disease, evaluating protein-based drug targets with 
novel endpoints for better treatment of various malignant diseases [Verma et al., 
2001].  
 
1.2 Cancer Detection and Molecular Biomarkers 
Cancer remains to be a major challenge to public health despite progress in 
detection and therapy. A large portion of the US population will develop cancer during 
their lifetime [Chaurand et al., 2001], with ~50,000 individuals dying annually from 
the disease [American Cancer Society, 1996]. With the better understanding of 
molecular basis of malignant diseases, cancer diagnosis and treatment has become 
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more target-oriented but still limited in the late invasive and metastatic stages. This in 
turn greatly limited the success of treatment. It is generally accepted that if molecular 
targets in the earliest stage of tumor growth can be identified, the treatment of cancer 
is likely to be more effective and successful [Negm et al., 2002].  
Molecular markers are defined as detectable species that are characteristic in 
case of an organism’s state of health or disease, or are responsive to a particular 
clinical treatment [Negm et al., 2002]. It is known that changes in molecular levels 
occur at the beginning of the tumor growth. To detect these changes, diagnostic assays 
using molecular biomarkers have considerable potentials for early cancer detection.  
Proteomics, especially serum proteomics, is unquestionably valuable in the 
discovery of biomarkers. Proteomes could reflect both the genetic coding of the cell 
and the impact of their surrounding microenvironment. Due to altered expression, 
posttranslational modification and other intra- or inter-cellular events, distinguishable 
changes will occur at the protein level during the transformation of healthy cells into 
cancer cells [Banks et al., 2000]. Therefore, the ability to make accurate measurement 
about the state of pathology (or health) within organ systems by analyzing the fluid 
that perfuses them, especially as in serum/plasma, has several major advantages. 
Firstly, for a biomarker (or set of biomarkers) to be clinically valuable, it must be 
disease-specific and be accurately detected. To some extent, components found in the 
serum represent the cumulative effect of disease processes in organ tissue, and some 
of those were not recognized by previous clinical practices. This makes serum a 
valuable source of molecular biomarkers with high expected specificity. And 
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moreover, because traces of the molecular footprints of on-going disease process are 
expected to equilibrate in the circulation system, the strong possibility of sampling 
error that is often associated with tissue biopsy is reduced substantially. Secondly, to 
be applicable for clinical uses, any source of biomarkers must be readily obtainable 
from the patient. Serum or plasma is one of the best sources for biomarker discovery 
and screening because phlebotomy can be repeated as often as needed. Therefore, 
serum investigations provide relative ease of sampling compared with the biopsy of 
solid organs. 
There are several clinical cases where molecular markers from serum are 
already being used. For example, increased serum levels of prostate-specific antigen 
(PSA) and cancer antigen-125 (CA-125) are routinely used for the detection of cancer 
in the prostate and ovary, respectively [Grossklaus et al., 2002; Guppy et al., 2002]. 
However, there are no molecular markers clinically available for most types of cancer 
in terms of early stage diagnosis, especially for several most deadly cancers such as 
lung cancer and breast cancer.  
 
1.3 Technologies Involved in Cancer Proteomic Research: 
1.3.1 Two-Dimensional Gel Electrophoresis 
Two-dimensional gel electrophoresis (2D-GE) has been the mainstay of 
electrophoretic technology for a decade and is one of the most widely used tools for 
separating proteins. In 2D-GE, proteins are first separated by isoelectric focusing (IEF) 
based on the charge state of proteins and then further resolved by sodium dodecyl 
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sulfate polyacrylamide gel electrophoresis (SDS–PAGE) in a second, perpendicular 
dimension according to their size. Separated proteins can then be visualized by all 
kinds of staining methods (Coomassie Blue and Silver stain, for example), or by 
autoradiography, producing a two-dimensional image that contains thousands of 
proteins [Klose et al., 1995]. The identification of proteins in each stained spot could 
be achieved using immunoblotting, N-terminal sequencing or tandem mass 
spectrometry [Hunter et al., 2002]. In many applications, 2D-GE was used to evaluate 
cell lysates, tissue, or biofluid protein extracts [Jiang et al., 2003; An et al., 2004; 
Vitorino et al., 2004]. The commercialized use of narrow, immobilized PH gradients 
for the first dimension can increase resolving power and help detect low-abundance 
proteins [Görg et al., 2000]. Differences between the samples can be compared and 
relative quantities determined by quantifying the spot intensity ratios in different 2D 
gels. Matrix-assisted desorption/ionization time-of-flight mass spectrometry 
(MALDI-TOF MS) and high resolution LC tandem mass spectrometry allow the 
identification and quantification of very small amounts of protein isolated from the 
gel. During last several years, increasing numbers of researches in cancer biomarker 
screening and discovery were reported using 2D differential gel electrophoresis 
(2D-DIGE, see Figure 1.1) coupled with mass-spectrometry [Arthur et al., 2002; 
Schulenberg et al., 2003; Friedman et al., 2004]. 
However, in spite of all these achievements made in the past decade, 2D-GE 
still suffers from several major limitations. These limitations includes: requirement of 
relatively large sample quantities (the limit for the detection of proteins with silver 
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staining is approximately 1 ng, i.e., 20 fmol for a 50 kDa protein [Shevchenko et al., 
1996], difficulties in detecting proteins with extreme molecular mass (large or small) 
and isoelectric point, limited dynamic range according to staining method used, poor 
reproducibility, labor intensive and difficulties in automating [Beranova-Giorgianni, 
2003].  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 7
  
 
 
Figure 1.1 Schematic illustration of the difference gel electrophoresis (DIGE) 
technology platform [“Detection technologies in proteome analysis”, Wayne F. Patton, 
2002]. Two different samples are derivatized with two different fluorophores, 
combined and then run on a single 2D gel. Proteins are detected using a dual laser 
scanning device or xenon arc-based instrument equipped with different excitation 
/emission filters in order to generate two separate images. Differences in protein 
expression are identified by evaluation of a pseudo-colored image and data 
spreadsheet. DIGE technology can maximally evaluate three different samples using 
Cy2-, Cy3- and Cy5-based chemistries. 
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1.3.2 Multidimensional Protein Identification Technology 
Multidimensional protein identification technology (MudPIT) is a method 
that couples a microscale two-dimensional chromatography system to a tandem mass 
spectrometer, which allows high-throughput analysis of a complex proteome (see 
Figure 1.2). First introduced by A. J. Link and colleagues, strong cation exchange 
(SCX) resin is placed upstream of the RP portion of the HPLC column [Link et al., 
1999], forming a in-line 2D HPLC separation system.  
Peptides are bound to the SCX phase first under acidic/low-salt environment 
and subsequently eluted off using multiple high salt pulses with higher PH buffers, 
followed by reversed phase separation of each subset of peptides. For analysis of even 
more complex protein mixtures, such as whole cell extracts and serum/plasma, greater 
separation and data acquisition capacity is required. Further optimizations in 
combinations of various HPLC methods, buffers, and even enhancement of general 
strategy have resulted in a much more advanced MudPIT [Washburn et al., 2001; 
Wolters et al., 2001]. All kinds of multidimensional chromatography coupled with 
tandem mass spectrometry have been developed recently. With the high efficiency 
micro capillary LC-MS or even nanoscale LC-MS, a lot of achievements have been 
reported in cell or serum/plasma proteome research [Chen et al., 2002; Wagner et al., 
2003; Chen et al., 2004]. Hundreds of proteins, including ~pg/ml low abundance 
(angiotensinogen precursor, cytokins, interleukin) proteins, can be detected and 
identified [Tirumalai et al., 2003]. Although mixed-bed packing in one HPLC column 
was a patented setup for the original MudPIT technology, the idea of 
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multi-dimensional separation coupled with MS/MS detection was well adapted for 
analyzing highly complicated proteomes. This strategy has played a very important 
role on proteomic biomarker discovery. 
 
1.3.3 Isotope-coded Affinity Tag 
The prototypical method to generate quantitative protein profiles based on 
stable isotope affinity tagging and MS is the isotope-coded affinity tag (ICAT) reagent 
method [Gygi et al., 1999]. The first generation reagents (see Figure 1.3) consist of a 
cysteine-reactive group, a linker that contains either heavy or light isotopes, and a 
biotin affinity tag.  
In ICAT reagent method (see Figure 1.4), two protein extracts representing 
different cell states (i.e. healthy and diseased) are treated with the isotopically light or 
heavy ICAT reagents, respectively. In this labeling step, ICAT reagents are covalently 
attached with cysteine residues. The labeled protein mixtures are then combined and 
digested using enzyme of choices (usually by trypsin). ICAT labeled peptides which 
contain cysteine residue(s) could be selectively isolated using affinity 
chromatography and analyzed by mass spectrometry. The relative abundance is 
determined by the ratio of signal intensities of the tagged peptide pairs. The MS/MS 
spectra are recorded and searched against protein sequence databases to identify the 
protein. Therefore, in a single operation, the relative abundance and sequence of a 
peptide can be determined [Tao et al., 2003].  
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Figure 1.2 The online MudPIT interface developed by Yates and colleagues [“Direct 
analysis of protein complexes using mass spectrometry”, A. J. Link et al., 1999]. It 
includes biphasic microcapillary column, packed with strong cation-exchange (SCX) 
and reversed-phase (RP) packing material connected to a microcross. The microcross 
splits the flow from the HPLC column to 0.15-0.25 uL/min and serves as the 
connection for the electrospray voltage.  
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Cysteine residues represent a good target to reduce the complexity of digests 
from large proteomes or other complex protein samples. This is because 96.1% of all 
human proteins are known to have cysteine residue(s) but only 26.6% of the peptides 
contain cysteine after tryptic digestion [Zhang et al., 2003]. Furthermore, there are 
other chemical methods available to target the SH group on the side chain of reduced 
cysteine [Zhou et al., 2002]. Therefore, cysteine becomes one of the most useful 
targets for residue-specific enrichment. And the isotope-coded affinity tag (ICAT) 
method has become widely used for quantitative proteome profiling. 
The second generation of ICAT reagent contains an acid-cleavable linker 
within the ICAT reagent molecule. This allows removal of the biotin affinity tag 
before MS and MS/MS analysis. The improved MS/MS performance will 
significantly increases the number of proteins identified in a single experiment and 
quantify them with higher confidence scores. Incorporation of 13C rather than 
deuterium into the ICAT heavy reagent molecule overcomes isotope-co-elution effect 
in reversed phase chromatography, thereby increases the accuracy of quantification 
measurements using LC-MS. Recently, Kubota et al. reported proteome analysis of 
secreted proteins during osteoclast differentiation using ICAT, together with 2D-GE 
and 2D LC-MS [Kubota et al., 2003]. Meehan et al. reported quantitative profiling of 
LNCaP prostate cancer cells using ICAT and mass spectrometry [Meehan et al., 
2004].  
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Figure 1.3 The structure of ICAT reagents [“Advances in quantitative proteomics via 
stable isotope tagging and mass spectrometry”,W Andy Tao and Ruedi Aebersold, 
2003]. ICAT reagents comprise a cysteine-reactive group, a linker containing either 
eavy or light isotopes and a binding affinity tag.  
 
 
h
 
Figure 1.4 The ICAT reagent strategy of quantifying differential proteins [“Advances 
in quantitative proteomics via stable isotope tagging and mass spectrometry”,W Andy 
ao and Ruedi Aebersold, 2003]. 
 
T
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A more recent study conducted by Molloy and colleagues pointed out an 
issue that using ICAT-MS technology tends to under represent low molecular weight 
basic proteins in the proteome [Molloy et al., 2005]. Their research also indicates that 
ICAT-MS technology was not much superior than 2-DE coupled with MS on 
detecting highly hydrophobic transmembrane proteins. This will surely limit the 
applicati
ssential quantitative 
producibility and sensitivity for general proteomic analysis.  
1.3.4 SE
phase protein chip surface (see Figure 1.5) before MALDI-TOF MS 
analysis.
on of ICAT-MS technology in these disciplines.  
All in all, ICAT MS technology provided e
re
 
LDI and Proteomic Pattern Analysis 
Surface-enhanced laser desorption/ionization time of flight MS (SELDI-TOF) 
is a novel approach introduced by Hutchens and Yip [Hutchens et al., 1993]. It 
combines various retention surfaces with MALDI mass spectrometry. Samples are 
captured by adsorption, partition, electrostatic interaction, or affinity chromatography 
on a solid-
  
Liotta and Petricoin’s group pioneered the use of SELDI-TOF MS for the 
detection of prostate and ovarian cancer based on proteomic pattern diagnostic 
approach [Petricoin III et al., 2002a,b]. It is suggested that this approach can 
successfully distinguish protein counterparts that differ by expression level, providing 
a fingerprint map of proteomic contents within different specimens. Its core 
hypothesis is that proteins or protein fragments produced by neoplastic cells may 
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eventually enter the blood circulation system. The abundance of these 
proteins/fragments could be analyzed directly with SELDI-TOF MS. A well designed 
mathematical algorithm is a must for data interpretation and the extracted infomation 
could be used for diagnostic applications. In addition to the original FDA group’s 
results, other groups also reported biomarker analysis of prostate cancer using 
SELDI-TOF proteomic pattern approach [Adam et al., 2002; Qu. Y et al., 2002; 
Banez et al., 2003; Lehrer et al., 2003]. A similar approach has also been utilized in a 
study on ovarian cancer [Kozak et al., 2003]. Metal affinity (IMAC-Cu), hydrophobic 
(C16 or H4) or weak cation exchange (WCX2) chips were used in these researches. In 
general, it has been suggested that this technology can achieve much higher 
diagnostic sensitivity and specificity (approaching 100%) in comparison to the 
lassical cancer biomarkers.  c
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Figure 1.5 The arrays consist of either 8 or 16 spots composed of a specific 
hromatographic surface [“Current developments in SELDI affinity technology”, 
ing Tang et al., 2004]. 
 
c
N
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1.4 Issues Associated With Current Human Serum/Plasma Proteome Research 
and Ou
 However, among all the 
roteins identified, the recovery rate of LMW proteins was only 15-20%, and most 
3%) of proteins were identified by only 1 unique peptide. 
 
r Strategy 
1.4.1 Dynamic Range Issue 
The concentration range of serum/plasma proteome is one of the major 
challenges in cancer marker detection. Among the high abundance group, serum 
albumin has a concentration of about 35-50mg/mL. At the low abundance end, 
interleukin 6 has a normal concentration range between 0-5pg/ml [Anderson et al., 
2002]. This extraordinary high dynamic range (106~109) exceeds most of the 
contemporary analytical methods, including high efficiency micro capillary LC-MS. 
Therefore, when targeting low abundance biomarkers, proper fractionation of proteins 
prior to the final detection and identification is a must for serum/plasma proteome 
researches. It has been reported that removal of serum albumin and immunoglobulins 
using affinity chromatography could enhance the detection of low molecular 
weight/low abundance proteins [Sato et al., 2002; Adkins et al., 2002]. However, 
those major protein components, especially albumin, in serum are well known to be 
carrier or transporter of other smaller proteins [Curry et al., 2002]. Therefore, many 
important low-molecular-weight (LMW) proteins/peptides could have been removed 
by affinity depletion process. R. S. Tirumalai and colleagues reported an ultrafiltration 
approach to deplete high abundance proteins and thus to enrich LMW portion of 
serum proteome [Tirumalai et al., 2003]. With 341 proteins identified, including very 
low abundance interlukins, their result is pretty attractive.
p
(8
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1.4.2 Quantification/Data Interpretation Issue 
The SELDI based approach is simple, can be high-throughput, and could be 
easily automated. However, despite the reported success on detecting cancer from 
serum, t
s a marker 
distingui
ce interfering proteins in a 
random 
he SELDI based approach using affinity protein chip has several intrinsic 
limitations, which may compromise the clinical use of this approach. 
The most serious issue encountered is its poor reproducibility. In fact, the 
findings from one lab are essentially not repeatable by others [See Table 1.1]. For 
example, the SELDI approach has been used by several groups to detect prostate 
cancer [Adam et al., 2002; Petricoin III et al., 2002; Qu. Y et al., 2002; Banez et al., 
2003; Lehrer et al., 2003]. Adam et al. found nine peaks, while Petricoin used 7 peaks 
to differentiate cancer from noncancer. Interestingly, none of the peaks were identical. 
Qu et al. who originally belonged to Adam’s group conducted the research using the 
same chip and the same instrument. A comparison of the results from these two 
groups yielded different sets of diagnostic peaks (in fact, only two peaks were 
identical). In addition, although Adam et al. identified a peak a
shing between cancer and noncancer, the same peak was used by Qu et al. to 
distinguish a healthy individual from a patient with benign hyperplasia.  
The reproducibility issue is believed to be caused by nonspecific interaction 
and saturation of protein chip surface with high abundan
manner. Without proper fractionation, analyzing serum samples directly on 
SELDI chips will not be able to overcome this obstacle.  
Reproducibility could be somewhat improved by the use of better algorithms 
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[Alexe et al., 2004; Petricoin et al., 2004]. It is also suggested that better 
quality-control and quality-assurance are critical for reducing variability and potential 
bias [Wulfkuhle et al., 2003; Petricoin et al., 2004]. However, what has been 
overlooked thus far is the non-quantitative and non-reproducible nature of the 
currently used SELDI-based serum proteomic pattern approach itself. The proteomic 
pattern analysis requires at least a semi-quantitative comparison of the relative 
intensity of a marker peak in both control and disease samples. Nevertheless, both 
direct serum protein extraction on chip and the following MALDI detection used in 
e SELDI approach are often biased and not quantitative, thus leading to poor 
reproducibility.  
 
th
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a. This table is from “Mass Spectrometry as a Diagnostic and a Cancer Biomarker 
Discovery Tool: Opportunities and Potential Limitations”[Eleftherios P. 
Diamandis, 2004]. 
b. M/Z ratios were rounded to whole numbers for simplicity. M/Z ratios in bold font 
represent those identified by Adam et al. and Qu et al. for differentiating cancer 
from non-cancer patients. The underlined M/Z ratio represents a peak identified 
by Adam et al. for differentiating cancer from non-cancer patients and by Qu et al. 
for differentiating healthy individuals from patients with benign prostatic hyper 
plasia. 
c. BPH, benign prostatic hyperplasia. 
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The goal of the first part of my dissertation is to develop a multidimensional 
fractionation strategy involving molecular weight cut-off (MWCO) ultrafiltration 
and/or other separation methods which can deplete high abundance proteins as well as 
retain and enrich low molecular weight (LMW) or low abundance proteins/peptides. 
Instead of struggling on perfect molecular weight cut-off, we will focus on efficient 
and quantitative recovery of targeted sub-proteome from human serum samples.  
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CHAPTER II 
SEPARATION AND ENRICHMENT OF FREE-PHASE AND BOUND 
LOW-MOLECULAR-WEIGHT FRACTION FROM HUMAN SERUM USING 
ULTRAFILTRATION FOR MALDI-TOF-MS PATTERN ANALYSIS 
 
 
 
2.1 Introduction 
After completed the Human Genome Project, researchers started a new 
journey exploring proteomes in various organism. Since proteins play a major role in 
the molecular pathways that drive all kinds of cellular functions, the elucidation of 
diseases’ mechanisms, such as cancer, requires further study and identification of 
these proteins [Ashcroft, 2002]. It was widely accepted that early detection is critical 
in cancer control and prevention. Proteomics study could help finding novel 
biomarkers and pathological pathways for early detection and prognosis. One of the 
major parts of cancer proteomics involves the identification of differentially expressed 
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proteins and quantitative comparison of those proteins at various disease stages with 
their counterparts in healthy specimen [Srinivas et al., 2001].  
Matrix-assisted desorption/ionization time-of-flight mass spectrometry 
(MALDI-TOF-MS) has been an important tool for proteomic research. Cell [Lee et al., 
2004], tissue [Pierre et al., 2001], cerebrospinal fluid [Davidsson et al., 1999], urine 
[Lin et al., 2006], plasma/serum [Kiernan et al., 2004; Wang et al., 2003], virtually 
any specimen that are commonly used for clinical research and disease diagnosis 
could be analyzed using MALDI-TOF-MS.  
Surface enhanced laser desorption/ionization time-of-flight mass 
spectrometry (SELDI-TOF-MS), a modified version of MALDI-TOF-MS, has also 
been used to generate protein profiles directly from plasma/serum. Promising results 
have been reported on ovarian cancer, prostate cancer, and lung cancer samples, 
several candidate markers have been found [Petricoin et al., 2002; Kozak et al., 2003; Banez 
et al., 2003; Zhukov et al., 2003]. 
However, using MALDI-TOF-MS to generate complete protein expression 
profiles of these complex biological samples encountered some difficulties, and they 
are either intrinsic from MALDI-TOF-MS, or directly derived from the complexity of 
the sample themselves. 
Serum, derived from plasma after clotting, contains 60-80mg/ml proteins. 
The major protein constituents of serum include albumin, immunoglobulins, 
transferrin, haptoglobin, and lipoproteins [Turner et al., 1970; Burtis et al., 2001]. In 
addition to these major constituents, serum also contains many other proteins that are 
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synthesized and secreted, shed, or lost from cells and tissues throughout the body 
[Wrotnowski, 1998; Kennedy, 2001]. It is estimated that up to 10,000 proteins may be 
commonly present in serum [Wrotnowski, 1998]. This makes serum a perfect 
reservoir of finding disease related biomarkers for various organs, including cancer. 
However, there is one major limitation for using MALDI-TOF-MS in serum 
proteomics. All species are not ionized equally. Species with higher abundance or 
better ionization will tend to depress the signal of those with much lower relative 
abundance. Therefore, with the presence of high abundance proteins in serum 
(albumin, for example, 35-50mg/ml in serum), it will be impossible to detect those 
low abundance proteins (e.g. C-reactive protein, osteoponin, and prostate-specific 
antigen, which are below 10ng/ml in serum) using MALDI-TOF-MS.  
One of the most widely adapted strategies for overcoming this dynamic range 
issue is to remove high molecular weight proteins, enabling the detection of 
remaining low molecular weight (LMW) proteins present in much lower 
concentration. Various immuno-affinity columns have been developed for high 
abundance protein depletion. Multiple affinity removal system (MARS) from Agilent 
Technologies could effectively deplete 7 major interfering high-abundant proteins 
(albumin, IgG, IgA, transferrin, haptoglobin, antitrypsin, and fibrinogen) from human 
plasma samples, by which eliminates approximately 88-92% of total protein. Removal 
of these abundant proteins improves the subsequent analysis of the serum sample by 
effectively expanding the dynamic range of the analysis. However, it is well known 
that HSA and immunoglobulins are functioning as carrier proteins in serum; many 
 24
important low molecular weight peptides/proteins (e.g. hormones) bound to them 
would be removed with their carrier proteins simultaneously [Zhou et al., 2004]. 
Because affinity methods used to deplete high abundance proteins under 
non-denaturing conditions, this may result in the loss of potential disease-informative 
LMW species. 
Ultrafiltration, using molecular weight cut-off (MWCO) membrane, is 
widely used to concentrate and purify macromolecules. Among these methods of 
protein separation and fractionation, ultrafiltration is relatively simple, less expensive, 
and can be used as a continuous process with high throughput at ambient temperature. 
However, previous studies using ultrafiltration were not very successful. Georgiou 
and colleagues [Georgiou et al., 2001] demonstrated that they had failed to completely 
remove HSA and other high abundance proteins using centrifugal ultrafiltration. But it 
was later pointed out by Tirumalai [Tirumalai et al., 2003] that using undiluted plasma 
and centrifuging under high speed (12,000xg) may be the cause of their failure. 
Triumalai and colleagues had compared the protein recovery under non-denaturing 
(i.e., 25 mM NH4HCO3, pH 8.2) and denaturing conditions (i.e., 25 mM NH4HCO3, 
pH 8.2 with 20% (v/v) acetonitrile). They found that the LMW fraction was 
successfully enriched. Highly diluted serum and much slower centrifuge speed 
(3000xg) were also proved to be effective for preventing HSA from leaking through 
the filter membrane. They managed to identify 341 unique proteins from low 
molecular fractions of serum using this improved procedure. 
Here we demonstrated the separation and enrichment of free-phase and 
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bound low molecular weight fraction in serum using MWCO ultrafiltration. Both 
elution and denaturing conditions were optimized to achieve robust proteomic pattern 
analysis using MALDI-TOF-MS and high quality protein identification using 
LC-MS/MS. The result showed that under optimized conditions, ultrafiltration may 
provide enough separation power to reproducibly elucidate potential biomarker 
information from low molecular weight fraction of human serum.  
 
2.2 Materials and Methods 
2.2.1 Materials and Reagents 
Milli-Q water was used for all solutions. Microcon® centrifugal filters (spin 
column) with a molecular weight cut-off (MWCO) of 30kDa and ZipTip® C18 
reversed phase pipette tips for sample preparation were purchased from Millopore 
Corporation (Berford, MA). Phosphate-buffered saline (PBS) solution, trifluoroacetic 
acid (TFA), HPLC grade acetonitrile, α-cyano-hydroxycinnamic acid (CHCA) were 
purchased from BIO-RAD (Hercules CA), Pierce (Rockford, IL), Aldrich Chemicals 
(Milwauke, WI), Bruker Daltonics (Billerica, MA), respectively. 
 
2.2.2 Human Serum Resources and Information 
Human serum from healthy donor was purchased from Sigma (St. Louis, 
MO). Serum was thawed upon arrival and aliquot into smaller fractions to minimize 
future freeze/thaw cycles. Most of method developments were done using this serum.  
Serum from ovarian cancer patients and normal controls was obtained from GOG 
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bank. Totally 20 ovarian cancer patient sample and 19 normal controls was used in 
this study. These serum samples were also divided into smaller fractions upon 
receiving and stored under -80 degree before further processing. 
 
2.2.3 Centrifugal Serum Ultrafiltration 
2.2.3.1 Free Phase Low Molecular Weight Fraction Collection 
The centrifugal filter membrane in Microcon® spin columns were rinsed and 
used according to the manufacturer’s instructions. 50µl serum was diluted with 250µl 
PBS (pH 7.4), and gently mixed on a vortexer for 2 minutes. The sample was spun at 
a speed of 14,000 rpm (~16,000xg on Eppendorf Centrifuge 5415C) for 10 minutes 
before performing ultrafiltration to precipitate any insoluble particles that may clog 
the membrane. The supernatant was then carefully pipetted into prepared centrifugal 
filter. The sample was centrifuged (Eppendorf Centrifuge 5415C, Brinkman 
Instruments, Westbury, NY, USA) at 5000 rpm for 30 minutes until about 90% of the 
input serum solution had passed through the membrane, meanwhile, make sure there 
was enough retentate left to avoid membrane dryness. An aliquot of 1xPBS solution 
was then added into the sample reservoir to dilute the retentate to 300µl, and the 
retentate was gently mixed by performing 10-15 aspirate-dispense cycles with pipette 
tip before another consecutive centrifuge. Such operation was performed 8 times 
totally. The filtrates in separate tubes were lyophilized to dry in Speed-Vac and 
resuspended in 50µl of 0.1% TFA solution before MS analysis.  
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2.2.3.2 Bound Low Molecular Weight Fraction Collection 
After free-phase low molecular weight (LMW) fraction being eluted, the 
retentate was collected by reversing the sample reservoir and centrifuging into a new 
collection tube at proper lower speed according to the instruction manual. The total 
volume of each retentate was about 30uL. It was then incubated with 100µl 8M urea 
for at least 2 hours under ambient temperature. After that, the elution of bound LMW 
fraction from denatured retentate was carried out in a new 30k MWCO spin column, 
and all the eluting operations were the same as described in section 2.3.1.  
 
2.2.4 MALDI-TOF-MS Pattern Analysis 
2.2.4.1 Sample Preparation 
ZipTip® C18 reversed phase pipette tips (Millopore, Billerica, MA) were used 
for de-salting and concentrating of peptides/proteins prior to MALDI-TOF-MS 
analysis. 10µl of the resuspended filtrates (free-phase or bound) were used for each 
clean-up process. The elution buffer is 10ul 50% acetonenitrile with 0.1% TFA if not 
otherwise mentioned. The reproducibility of this process was also tested using 
MALDI-TOF-MS pattern analysis of resuspended filtrates from three separate 
Microcon® spin columns. 
 
2.2.4.2 MALDI-TOF-MS 
Dried-droplet deposition of the sample was achieved by depositing 1µl (0.5µl 
each time, apply the rest after the first drop dried) of sample solution onto stainless 
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steel MALDI target, and then overlaid with 0.5µl of CHCA 
(α-Cyano-4-Hydroxycinnamic Acid) matrix solution (5mg/ml in 50% acetonitrile, 
0.1% TFA). For each sample, three duplicate spots were prepared to eliminate 
possible fluctuations. 
All mass spectra were collected using OminiFLexTM MALDI-TOF mass 
spectrometer (Bruker, Bilerica, MA, USA) operated in the linear, positive mode with 
delayed extraction turned on. OminiFLexTM MALDI-TOF mass spectrometer uses a 
337nm pulsed nitrogen laser, which has a duration of 3ns and a full power of 175µJ. 
MS spectra were collected in the range of 700-10000 m/z ratio. All experiments were 
performed under 75% of full laser power with sampling rate of 5Hz if not otherwise 
specified. 10 sampling points were randomly picked on each sample spot. One 
hundred shots per sampling points were accumulated and all 10 sets of spectra were 
combined to eliminate on-target fluctuation.  
 
2.2.5 LC-MS/MS Analysis and Protein Identification 
2.2.5.1 Trypsin Digestion 
The collected LMW species were concentrated to 80μL/sample using 
speed-vac and the PH of the solutions is adjusted to 7.8 using freshly made 100mM 
NH4HCO3 if necessary. Trypsin digestion was conducted in solution using standard 
procedure with some modifications. In general, there was no denaturation, reduction, 
and alkylation before adding trypsin. The first dose of trypsin was added at a ratio of 
1:100 (w/w) and incubated under 37  for 4 hours. The second dose of trypsin (1:50 ℃
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w/w) was added afterwards and incubated overnight under 37 . T℃ ryptical digests 
were frozen under -20  before further analysis.℃  
 
2.2.5.2 LC-MS/MS Analysis and Protein Identification  
The LC-MS/MS analysis was performed on Agilent 1100 HPLC system 
coupled in-line with a Bruker HCT 3000plus ESI-IonTrap Mass Spectrometer. 20μL 
tryptic digested sample was injected and eluted from a Vydac C18 capillary RP-HPLC 
column (10cm, 300µm ID) using the following gradient: 2% B, 10min; 5%-45% B, 
200min; 45%-85% B, 30min; 85%B, 30min. Solvent A is 0.1% formic acid and 1% 
acetonitrile in Milli-Q H2O, solvent B is 0.1% formic acid in acetonitrile. 
Tendem MS data were merged into one single data file for both free-phase and bound 
species. It was searched against NCBInr protein database using an in-house Mascot 
server. The search was performed using no enzyme, trypsin, trypsin+chymotrypsin 
separately and the results were combined. No taxonomy or modifications were 
specified. Peptide mass tolerance is ±1.0Da, MS/MS tolerance is ±0.5Da, and 
searched for all possible charge states (i.e. +1, +2, +3). The final result was manually 
inspected to remove all false positives. 
 
2.3 Results and Discussion 
2.3.1 Centrifugal Ultrafiltration 
Centrifugal ultrafiltration has long been used as clean-up/concentrating 
method on bio-macromolecules such as DNA and proteins. The unique molecular 
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weight cut-off membrane provided fast sample processing and high recovery rate. 
However, when used on serum proteomics, especially for high-abundance protein 
depletion, this method required special optimization.  
Tirumalai [Tirumalai et. al., 2003] and Harper [Harper et al., 2004] had investigated 
how experimental conditions, e.g. sample preparation, centrifugation time and speed, 
sample size and protein concentration, would effect the result of centrifugal 
ultrafiltration fractionation of serum. Some key factors had been pointed out but the 
results were still far from satisfactory.  
In our study, we introduced a systematic way of evaluating the performance 
of centrifugal ultrafiltration in low molecular weight serum proteome studies. The 
schematic demonstration of the strategy is shown in Figure 2.1. 
In previous study [Tirumalai et. al., 2003], low molecular weight fractions 
collected under non-denaturing and denaturing conditions were compared. As a 
conclusion, much more proteins/peptides could be detected under denaturing 
condition. Therefore denaturing conditions should be preferred and free-phase species 
eluted under non-denaturing conditions was neglected. However, our study showed 
that the amount of free-phase species could be much larger than people had thought 
before.  
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Figure 2.1 A schematic representation of separating and enriching free-phase and 
bound peptides from serum using centrifugal ultrafiltration and MALDI-TOF pattern 
analysis. 
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In our study, serum sample was diluted with PBS to prevent denaturing 
serum proteins, which minimized the disassociation of low molecular weight fraction 
from major carrier proteins. A low centrifuge speed was also adapted from previous 
studies to avoid protein leaking. Furthermore, we have found that only filtering once 
was not sufficient enough to completely elute free peptide/proteins. A total of 8 
consecutive ultrafiltrations under non-denaturing condition were performed to 
maximally separate free-phase peptide/proteins. A SDS-PAGE analysis was 
performed to demonstrate the effect of this process (See Figure 2.2). 
According to the results in Figure 2.2, it was after 6 consecutive 
non-denaturing ultrafiltrations when the amount of LMW proteins could be neglected. 
During consecutive centrifuge process, the retentate was carefully resuspended by 
gently performing aspirate-dispense cycles with pipette tip while not touching the 
membrane, which could maximally avoid protein accumulation on the membrane and 
pore clogging. The aspirate-dispense cycles made the solution be homogeneous 
without concentration gradient, which resulted in uniform experimental conditions for 
each ultrafiltration.  
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Figure 2.2 SDS-PAGE analysis of free-phase and bound peptides in serum using 
ultrafiltration with 30kDa cut-off spin column.  
Lane 1: Molecular weight marker;  
Lane 2 to Lane 5: Free-phase peptides, eluant 1 and 2, 3 and 4, 5 and 6, 7 and 8 
combined respectively;  
Lane 6 to 9: Bound peptides, eluant 1 and 2, 3 and 4, 5 and 6, 7 and 8 combined 
respectively. 
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The retentate part containing large carrier proteins was then incubated with 
8M urea solution, resulting in the disruption of the protein/protein interaction and 
separation of bound peptide/proteins from their carrier proteins. Thereafter, the 
denatured retentate was filtrated with a new 30kDa molecular weight cut-off spin 
column to collect the bound LMW species. PBS solution was used to dilute the 
denatured protein solution and the elution of dissociated species. This could ensure 
similar elution efficiency and minimize buffer effect during ultrafiltration procedure. 
No gel-like precipitate or membrane clogging was observed during the ultrafiltration 
of denatured proteins.  
As could be seen in Figure 2.2, the amount of low molecular weight 
proteins/peptides greatly increased after denaturing ultrafiltration. Moreover, most of 
LMW fraction disassociated from their carrier proteins by denaturing also can be 
completely eluted after 8 consecutive filtrations. And the components in free-phase 
LMW fractions were dramatically different (smaller molecular weight) from those 
eluted in bound fractions. The result clearly indicated the selective enrichment of both 
free-phase and bound species. The reproducibility of this consecutive ultrafiltration 
process was examined by MALDI-TOF MS pattern analysis using combined mixture 
of 8 eluants for free-phase and bound peptides, respectively. The results were shown 
in Figure 2.3. 
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Figure 2.3 MALDI-TOF spectra obtained from the samples filtrated by three different 
spincolumns. 
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As indicated in MALDI-TOF MS pattern analysis, the free-phase peptides 
demonstrated major difference from bound fraction. A side by side comparison 
indicated that some major small molecular weight peaks in free-phase protein/peptide 
samples disappeared or become weaker in bound peptide spectra, and many peaks 
with larger M/Z ratio were much more abundant in bound protein/peptide spectra. 
This is consistent with SDS-PAGE results. In summary, the ultrafiltration strategy we 
developed can lead to both enrichment of LMW serum peptides and separation of 
free-phase proteins/peptides from bound ones. Another important observation is that 
the total quantity of the free-phase proteins/peptides is comparable to that of the 
bound species in serum. 
A series of test were carried out to verify that the increased quantity of 
proteins after denaturation was neither yielded by the effect of membrane clogging 
during centrifugal ultrafiltration (free-phase proteins/peptides leftover on membrane), 
nor by the solvent elution efficiency difference between PBS and 8M urea.  
Firstly, the retentate containing high molecular weight carrier proteins was 
collected by placing the sample reservoir of Microcon spin column upside down, and 
spun at a proper low speed according to the instruction manual. One part of collected 
retentate was denatured and filtered in the same used Microcon spin column. Before 
reusing, the used empty column was spun twice using PBS to remove possible 
proteins/peptides leftovers on the membrane. In fact, no bands were observed for 
collected filtrates on SDS-PAGE analysis (data not shown). And then the denatured 
retentate was spun 8 times in washed used column using PBS as elution buffer. The 
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other part of retentate was spun using used Microcon spin column directly without 
washing. A third part of retentate was denatured and filtered using new clean 
Microcon spin column, following procedure described before. MALDI-TOF MS 
pattern analysis results were compared for these 3 differentially collected bound 
peptide samples (see Figure 2.4A, B, C, respectively). 
Secondly, the combined free-phase filtrates in PBS solution were also tested 
in a similar manner, except one part was eluted directly with PBS for 8 times, the 
other was incubated with 8M urea and then eluted 8 times with PBS. Both of them 
were filtrated with using new spin columns. MALDI-TOF MS pattern analysis results 
were also compared for these 2 differentially collected free-phase peptide samples in 
Figure 2.4D and 2.4E. 
As seen in Figure 2.4, with a slight difference of peak intensity, almost 
identical proteomic patterns had been generated in each group of tests. Denatured 
retentates generated completely deferent pattern from free-phase eluants. The patterns 
are almost identical with their counterparts in Figure 2.3. These results suggested that 
the decreasing quantity of free-phase peptides after multi-centrifugal ultrafiltration 
and the increase in quantity of low molecular weight fraction after urea denaturation 
were not resulted from membrane clogging or solvent effect. Separation of free-phase 
LMW species, dissociation and enrichment of bound proteins/peptides from large 
carrier proteins were achieved effectively using urea denaturatoin and centrifugal 
ultrafiltration. 
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Figure 2.4 Test of membrane clogging and solvent efficiency after 8 consecutive 
ultrafiltration.  
 
A. MALDI-TOF spectra of the re-centrifugal ultrafiltration of bound peptides from 
serum, using used spin column without additional wash. 
B. MALDI-TOF spectra of the re-centrifugal ultrafiltration of bound peptides from 
serum, using used spin column after additional wash. 
C. MALDI-TOF spectra of the re-centrifugal ultrafiltration of bound peptides from 
serum, using new spin column. 
D. MALDI-TOF spectra of the re-centrifugal ultrafiltration of free-phase peptides 
from serum, eluted after 8M urea incubation.  
E. MALDI-TOF spectra of the re-centrifugal ultrafiltration of free-phase peptides 
from serum, eluted directly with PBS solution. 
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2.3.2 MALDI-TOF Pattern Analysis - Method Development 
MALDI-TOF pattern analysis was introduced in human serum proteomic 
research by Patricoin and Liotta [Petricoin III et al., J. Natl. Cancer Inst. 2002, Lancet 
2002]. Although the original SELDI approach resulted in debatable data [Diamandis, 
2004], the idea of using differential comparison of healthy and patient proteomic 
patterns for biomarker discovery is still a widely accepted strategy. 
We developed a data acquisition procedure to robustly generate easy to read 
proteomic patterns using MALDI-TOF MS. Every pattern was a combined spectrum 
from 10 randomly selected sampling spots with 100 shots per spot for each sample 
deposited on target. This would reduce spot to spot variation during sample 
preparation in MALDI-TOF MS (known as “hot-spot effect”).  
One set of MALDI-TOF MS spectra were collected from three MALDI 
samples deposited on target using the same eluted LMW proteins/peptides. It was 
seen that with the averaging effect, both the proteomic pattern and the relative 
intensity of peaks were highly reproducible. And all combined spectra had shown 
strong signal intensity with high resolution (data not shown). This made visual 
identification of potential biomarker peaks a much easier job to do. 
 
2.3.3 Protein Identification Using LC/MS/MS with Database Searching 
Protein identification results using LC/MS/MS with database searching were 
summarized in Table 2.1. 
At first look, we identified less proteins compared with previous study. But 
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our strategy has several advantages. Firstly, the data quality and the confidence level 
of identification were much better than previous study. As mentioned before, our 
8-cycle elution strategy could ensure complete collection of LMW species. 
Enrichment of free-phase and bound peptides in two different step also could be 
considered as an extra fractionation besides reversed-phase HPLC separation. Without 
interferences from large high abundance proteins, the sensitivity of high resolution 
mass spectrometry was further extended to detect low molecular weight fragments. 
Secondly, since the strategies used in both studies were focused on low molecular 
weight species in human serum, the number of LMW proteins detected should be an 
important factor to evaluate the efficacy of the method. As indicated in table 1, our 
method demonstrated much better result than previous study (90 LMW proteins 
identified in our study v.s. 69 in previous study). Lastly, fragments from same protein 
could be collected separately in both free-phase and bound fractions. So combining 
MS/MS data before database searching could be one of the essential factors for 
protein identification. Searching against non-tryptic fragmentation also could help 
identify LMW species naturally present in serum. 
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Table 2.1 Protein Identification Result Compared With 
Previous Study [Tirumalai et al., 2003] 
  Previous Study Our Result 
Total Proteins Identified 341 226 
# of proteins Identified by only one unique 
peptide 285 (83.5%) 36(16%) 
# of proteins with predicted MW higher than 
Cut-off MW (30kDa) of spin colum  282 (82.7%) 136 (60.2%) 
# of proteins with predicted MW lower than 
20k 38 (11%) 32 (14%) 
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2.3.4 Biomarker Discovery Using MALDI-TOF Pattern Analysis 
We were able to test our whole proteomic strategy on some clinical samples 
obtained from GOG bank. A total of 39 serum samples were tested in our project. 
There are 20 patient samples with ovarian cancer and 19 normal serum samples as 
control set.  
All experimental setup was the same as described above. MALDI-TOF 
pattern analysis was performed for free-phase LMW peptides, 
free-phase-peptide-removed denatured LMW peptides and directly denatured LMW 
peptides. All spectra were externally calibrated and normalized before bioinformatic 
analysis. 
Significant differences were found between cancer patient and normal control 
when comparing free-phase peptide patterns. Same results were also found when 
using directly denatured peptide patterns. Based on previous test results on centrifugal 
ultrafiltration method, we could conclude that these differences were contributed 
solely by free-phase peptides. 
A typical pattern comparison was shown in Figure 2.5a. As could be seen, 
three peaks were identified to differentiate cancer patients and normal control. To 
further compensate for the intrinsic disadvantage of quantification using 
MALDI-TOF MS, we used relative peak intensity ratio instead of peak intensity itself 
to define cut-off thresholds. So there are 2 marker ratios used to distinguish cancer 
and normal samples: M1/M2>1 and M1/M3>1. Both of them have to be satisfied for 
positive classification of cancer. It could not be classified in either of the two groups if 
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only one of them is satisfied.  
Using these markers, 16 out of 20 cancer patients (80%) were correctly 
identified. In the 4 misclassified samples, only 1 demonstrated a “normal” pattern 
(M1/M2 and M1/M3 are all smaller than 1). We failed to detect any marker peaks in 
the other 3 samples (as could be seen in Figure 2.5b). 
Correct marker ratios (M1/M2<1 and M1/M3<1) were found in 79% of 
normal samples. There were 2 samples that demonstrated false positive signals, and 
the other 2 samples could not be classified in either group.  
A t-test was also performed to verify the statistical significance of our results. 
With an assigned p-value threshold as 0.05, marker ratio 1 (M1/M2) between two 
sample groups has a p-value of 0.0009, and marker ratio 2 (M1/M3) is 0.04, all 
indicating significant differences between patient and normal samples. Better results 
could be obtained if we discard the 3 patient samples without any marker peaks 
(M1/M2 p-value=0.0002 and M1/M3 p-value=0.025). 
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Figure 2.5a. MALDI-TOF-MS pattern analysis of ovarian cancer patient serum and 
normal serum. 
 
Figure 2.5b. Software generated “virtual gel” indicating selected marker peaks in 2 
sample sets. 
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2.4 Conclusion 
In this project, we evaluated a new application of centrifugal ultrafiltration in 
human serum proteome study. Our results demonstrated successful separation and 
enrichment of free-phase proteins/peptides and proteins/peptides bound to large 
carrier proteins in serum.  
Combining centrifugal ultrafiltration with MALDI-TOF MS pattern analysis, 
we selected 3 marker peaks for differentiating ovarian cancer patients and healthy 
controls. And we believe that these markers were found from free-phase fractions. 
The sensitivity and specificity are 80% and 79%, respectively (using peak intensity 
ratios). This is only a small pilot study with limited number of samples. More 
validation should be done with larger sample sets using more standardized 
procedures.  
Based on the procedure we used in centrifugal ultrafiltration, a more accurate 
definition for so called “free-phase” species should be “free and less tightly bound 
molecules”, and this part of serum proteome was somehow ignored in previous 
studies. Our results agreed with previous studies on the supreme complex nature of 
serum proteome but provided new possibilities of finding potential biomarkers.  
It will never be emphasized enough about the importance of removing high 
abundance proteins before further study of the rest of serum proteome. However, 
removal should not be the ending of these hard-working carriers. Each one of them 
might represent a whole new sub-proteome and further thorough exploring may lead 
to a world we never know. 
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CHAPTER III 
A NOVEL PROTEOMIC APPROACH USING ORGANIC SOLVENT 
PRECIPITATION AND ENZYMATIC DEGLYCOSYLATION FOR 
ELUCIDATING OVARIAN CANCER MARKERS IN HUMAN SERUM 
 
 
 
3.1 Introduction 
During the last decades, proteomics has been well accepted as a new 
systematic tool of understanding various biological disorders. High sensitivity and 
automated mass spectrometric techniques have been developed to enhance the 
capability of analyzing highly complex biological samples.  
However, there are still considerable limitations. When encountering whole 
proteomes, the extraordinary dynamic range of protein components in a single cell, or 
in plasma and serum has long been a huge obstacle before researchers. A 7-10 orders’ 
difference in concentration is surely out of the reach of any single contemporary 
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proteomic techniques [Stasyk and Huber, 2004].  
Pre-fractionation of the whole proteome before further analysis has been a 
widely used strategy especially when focusing on biomarker discovery in low 
molecular weight (LMW) fraction of human plasma/serum. Centrifugal ultrafiltration 
has been used to separate and enrich the LMW serum proteome [Tirumalai et al., 
2003]. And it has also been used to demonstrate the complicated interactions between 
serum proteins [Zhou et al., 2004]. Various immuno-affinity columns have been 
developed to conveniently remove high abundance proteins from human serum 
[Bjöhall et al., 2005], and a similar approach using affinity spin tube filter was also 
shown to be effective [Wang et al., 2003].  
However, there is one limitation associated with direct removal of large high 
abundance proteins. In serum, dominating proteins such as albumin are known to be 
carriers and transporters of proteins and other species [Schussler, 2000; Curry, 2002; 
Dea et al., 2002]. Removal of LMW species spontaneously with their carriers may 
greatly effect further identification and quantitative analysis. Therefore, disrupting 
protein-protein interactions before removal of high abundance carrier proteins is an 
essential step for LMW serum proteomic research. Tirumalai and Zhou demonstrated 
that using centrifugal ultrafiltration under denaturing conditions could effectively 
deplete high abundance large proteins as well as separate and enrich LMW proteins in 
human serum; several new low abundance proteins in serum proteomic study has been 
identified, too [Tirumalai et al., 2003; Zhou et al., 2004]. In our previous study (see 
Chapter II), centrifugal ultrafiltration was used under optimized conditions to 
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separate and enrich both free-phase and bound LMW species in human serum. 
Furthermore, a series of potential markers were identified for distinguishing ovarian 
cancer patients and normal controls using MALDI-TOF MS pattern analysis.  
A novel approach using organic solvent extraction as a sample preparation method for 
mass spectrometry based proteomic analysis has been reported recently [Chertov et al., 
2004]. They were using 50% acetonitrile solution with 0.1% trifluoroacetic acid as 
denaturing reagent to extract LMW proteins/peptides from both turmor challenged 
mice serum and normal human serum samples. The following surface enhanced laser 
desorption/ionization (SELDI) TOF MS analysis identified several differentially 
expressed protein markers. Compared with centrifugal ultrafiltration, organic solvent 
precipitation is simple and effective on high abundance protein removal and LMW 
protein enrichment.  
In this study, we demonstrated an organic solvent precipitation approach on 
detecting serum biomarkers for ovarian cancer. High concentration of acetonitrile 
solution (80%) was used to improve high abundance protein depletion. An enzymatic 
deglycosylation step was added before MALDI-TOF MS pattern analysis. It was 
proved that for complex samples such as serum extract, deglycosylation could reduce 
suppression effect and improve signal to noise ratio within low molecular weight 
range. Biomarkers found from previous study were further evaluated and verified. 
One of the major marker peaks was identified as des-alanine fibrinopeptide A and this 
marker could be used to distinguish benign, carcinoma and non-cancer samples 
successfully. 
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3.2. Methods and Materials 
3.2.1 Materials 
HPLC grade acetonenitrile was purchased from sigma (St. Louis, MO). 
PNGase F (500 units/μL) was purchased from New England Biolabs (Ipswich, MA). 
An aliquot of enzyme was diluted to 5units/μL immediately upon receiving with 
supplied 1x G7 reaction buffer (50 mM sodium phosphate, pH 7.5) and stored at 4℃ 
until use. Microcon® centrifugal filters (spin column) with a molecular weight cutoff 
(MWCO) of 30kDa and ZipTip® C18 reversed phase pipette tips were purchased from 
Millopore Corporation (Berford, MA). Peptide calibration standard (1000~4000Da) 
and ultra-pure α-CHCA (α-cyano-hydroxycinnamic acid) matrix were purchased from 
Bruker Daltonics (Billerica, MA).  
 
3.2.2 Serum Sample Information 
Serum samples were obtained from multiple institutions. The first sample set 
was obtained from Gynecologic Oncology Group tissue bank (18 normal, 20 patients). 
All patients were diagnosed to have advanced stage ovarian cancer: 17 papillary 
serous carcinomas, 1 endometrioid carcinoma, 1 clear cell carcinoma and 1 unknown 
type.  
The second sample set was obtained from Cooperative Human Tissue 
Network – University of Pennsylvania Medical Center. There are 19 samples totally, 
and they may have diseases other than cancer but no detailed information available. 
One of them was from male donor and therefore excluded from our study.  
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The third sample set was again obtained from Gynecologic Oncology Group 
tissue bank (40 carcinomas and 20 benign). In cancer patient samples, there are 20 
papillary serous carcinomas, 10 mucinous carcinomas, 5 endometrioid carcinomas 
and 5 clear cell carcinomas. In samples from benign diseases, there are 10 serous 
benign, 5 mucinous benign and 5 other benign.  
All serum samples were aliquot to small fractions and stored under -80℃ 
before use.  
 
3.2.3 Denaturation of Serum and Separation of LMW Species 
40μL of serum was diluted and denatured in 2mL of 80% acetonenitrile in a 
15mL centrifuge tube. After immediate vortexing, the solution was centrifuged 
(Beckman Coulter Allegra™ X-22R centrifuge with Beckman F0685 fixed angle rotor) 
at 10,000 rpm (~10500xg) for 3 minutes to collect precipitated proteins. 1500μL of 
supernatants (equivalent to 30μL serum extracts) were carefully transferred into a 
2mL centrifuge tube and evaporate to 250μL using speed-vac. The sample is now 
ready for deglycosylation.  
 
3.2.4 Deglycosylation 
The pH of extracted sample was adjusted to 7.8 using 100mM NH4HCO3 
solution. 25 units (5ul 5units/ul solution) of PNGase F were added to each sample and 
gently mixed. All samples were incubated at 37  overnight. The next day, the ℃
reaction were stopped by freezing samples under -20℃. 
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After deglycosylation, 20μL of each sample (equivalent to ~3μL serum 
extract) was desalted using C18 Ziptip™ pipette tips following procedures slightly 
modified from manufacturer’s instruction. The only change is that we used 10μL of 
50% and 80% acetonenitrile each to elute the desalted peptides off Ziptip™ and 2 
aliquots were then combined and concentrated to ~2μL before applied on MALDI 
target. 
 
3.2.5 MALDI-TOF Pattern Analysis 
Desalted samples were applied on stainless steel MALDI target first. After all 
samples are applied and dried, 0.3μL of matrix solution (5mg/mL α-CHCA in 50% 
acetonenitrile, 0.1% TFA) was applied on top of each sample.  
All mass spectra were collected using OminiFLexTM MALDI-TOF mass 
spectrometer (Bruker, Bilerica, MA, USA) operated in the linear, positive mode with 
delayed extraction turned on. OminiFLexTM MALDI-TOF mass spectrometer uses a 
337nm pulsed nitrogen laser, which has a duration of 3ns and a full power of 175µJ. 
MS spectra were collected in the range of 700-10000 m/z ratio. All experiments were 
performed under 77% of full laser power with sampling rate of 2Hz if not otherwise 
specified. 3 sampling points were randomly picked on each sample spot. One hundred 
shots per sampling points were accumulated and all 3 sets of spectra were combined 
to eliminate on-target fluctuation. For those samples with low signal intensity, the first 
10 spectra were discarded to minimize matrix effect and get better signal to noise ratio 
within targeted m/z range.  
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The mass-spectrometer was calibrated with peptide calibration standard 
(1000~4000Da) from Bruker, and all samples were then calibrated externally and 
normalized.  
 
3.2.6 LC-MS/MS Analysis and Protein Identification 
3.2.6.1 Trypsin Digestion 
After MALDI-TOF-MS pattern analysis, samples from GOG bank (18 
normal samples and 20 cancer patient samples) were combined into 2 general 
mixtures: patient and normal. One half of combined LMW species were concentrated 
to 80μL/sample using speed-vac and the PH of the solutions is adjusted to 7.8 using 
freshly made 100mM NH4HCO3 if necessary. Trypsin digestion was conducted in 
solution using standard procedure with some modifications. In general, there was no 
denaturation, reduction, and alkylation before adding trypsin. The first dose of trypsin 
was added at a ratio of 1:100 (w/w) and incubated under 37℃ for 4 hours. The second 
dose of trypsin (1:50 w/w) was added afterwards and incubated overnight under 37℃. 
Tryptical digests were frozen under -20℃ before further analysis. 
 
3.2.6.2 LC-MS/MS Analysis and Protein Identification  
The LC-MS/MS analysis was performed on Agilent 1100 HPLC system 
coupled in-line with a Bruker HCT 3000plus ESI-IonTrap Mass Spectrometer. 20μL 
tryptic digested sample was injected and eluted from a Vydac C18 capillary RP-HPLC 
column (10cm, 300µm ID) using the following gradient: 2% B, 10min; 5%-45% B, 
 53
200min; 45%-85% B, 30min; 85%B, 30min. Solvent A is 0.1% formic acid and 1% 
acetonitrile in Mili-Q H2O, solvent B is 0.1% formic acid in acetonitrile. 
Tandem MS data were searched against NCBInr protein database using an 
in-house Mascot server. The search was performed using no enzyme, trypsin, 
trypsin+chymotrypsin separately and the results were combined. No taxonomy or 
modifications were specified. Peptide mass tolerance is ±1.0Da, MS/MS tolerance is 
±0.5Da, and searched for all possible charge states (i.e. +1, +2, +3). The final result 
was manually inspected to remove all false positives. 
 
3.3 Results and Discussion 
3.3.1 MALDI-TOF Pattern Analysis of GOG Bank Serum Samples 
In previous study (see Chapter II), we have demonstrated separating and 
enriching low molecular weight proteins/peptides in human serum using an optimized 
centrifugal ultrafiltration method. Three marker peaks (1260Da, 1465Da, 1545Da, 
respectively) were found and used to distinguish between cancer and normal samples. 
In this project, we developed a new organic precipitation method to extract LMW 
species from human serum. To validate the efficacy of our method and the markers we 
found before, we used MALDI-TOF pattern analysis coupled with this new method to 
test the same set of samples from Gynecologic Oncology Group tissue bank (18 
normal, 20 patients). 
A typical MALDI-TOF pattern comparison of the interested mass range 
(1200-1600Da) was shown in Figure 3.1. As could be seen, there are three marker 
 54
peaks which could be used to distinguish cancer patient and normal control. 1260Da 
and 1465Da peaks were the same peaks found using centrifugal ultrafiltration method 
in previous study. Interestingly, the 1545Da peak disappeared in most of the samples, 
and a new 1535Da peak could be detected. If we use peak area ratio 
1465Da/1260Da>1 as marker for cancer-positive, 14 out 18 normal samples could be 
correctly classified (77.8% specificity), and 1535Da peak was not detectable in most 
of the normal samples. 100% specificity could be achieved if using 
1466Da/1260Da>2 as marker. In case of sensitivity, 16 of 20 patient samples could be 
correctly identified using either 1465Da/1260Da>1 or 1465Da/1260Da>2 as 
distinguishing threshold.  
There were 3 patient samples (G239, G252, G502) with no signal detected 
within 1200-1600Da range using centrifugal ultrafiltration method in previous study. 
No signal was detectable in these samples using organic precipitation method either.  
Based on the results above, we could conclude that the organic precipitation method 
we developed could achieve similar results as in previous study. The specificity is 
even better when using optimized cut-off threshold (1465Da/1260Da>2).  
According to the SDS-PAGE result from Chertov group [Chertov et al., 
2004], protein precipitation using 50% acetonitrile could not completely separate low 
molecular weight species from their carrier proteins; a large amount of LMW species 
were still detectable in the precipitated fractions on denaturing gel. This observation 
indicated that the rapid denaturation of carrier proteins may result in co-precipitation 
of some LMW species bound to them. And only free-phase and less tightly bound 
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species could be sufficiently extracted in the supernatant. This could explain why we 
got very similar proteomic pattern between organic solvent precipitation method and 
non-denaturing centrifugal ultrafiltration method previously developed (data not 
shown).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 56
  
 
 
 
Figure 3.1 MALDI-TOF MS pattern analysis of serum samples from GOG bank.  
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3.3.2 Protein Identification Using LC/MS/MS and Database Searching 
Since we could repeatedly detect several marker peaks using two different 
methods, the identity of those peaks has to be revealed. LC/MS/MS analysis and 
database searching were performed on tryptic digested normal and patient samples. 
The most important marker peak at 1465Da was identified as 
des-alanine-fibrinopeptide A (2-16, DSGEGDFLAEGGGVR, See Figure 3.2). And 
the result also indicated that intact fibrinopeptide A (1535Da) and its other fragments 
(1350Da, 1263Da, 1206Da) were corresponding to several major peaks detected 
within 1200-1600Da mass range in MALDI-TOF patterns. But none of these peaks 
had shown consistent correlation with ovarian cancer and therefore wasn’t used as 
marker in our study. The intact fibrinopeptide A (1-16, ADSGEGDFLAEGGGVR, 
1535Da) is much less abundant than its major fragment - 1465Da - in cancer patient 
samples and was not detectable in most of the normal samples (where 1465Da marker 
peak is also very weak). According to previous study [Profumo et al., 2005], 
des-alanine fibrinopeptide A (fpAY) should be a less abundant form compared with 
the original whole peptide after thrombin induced fibrinogen activation. But in our 
study, it is the major distinguishing peak and the relative quantity is much higher than 
the intact fibrinopeptide A and other fragments in benign and cancer patient samples. 
This may indicate some pathological change related to cancer development.  
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Figure 3.2 LC/MS/MS analysis and database searching result for marker peak at 
1465Da.  
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The identity of the 1260Da peak is still unknown even after LC/MS/MS 
analysis and database searching. Comparing MALDI-TOF patterns with or without 
deglycosylation indicated that the relative intensity of 1260Da peak decreased after 
deglycosylation in some samples (see Figure 3.3). This indicated that a N-linked 
oligosaccaride was removed after deglycosylation using PNGase F. Enzymatic 
deglycosylation treatment made the relative intensity of 1260Da peak more stable and 
reliable. It could serve as a good internal standard because it is not related to 
fibrinopeptide A and is less affected by the suppression effect generated from high 
levels of fibrinopeptide A fragments.  
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Figure 3.3 Relative intensity changes of 1260Da marker peak before and after 
enzymatic deglycosylation in some samples. It should be noted that the adjacent 
1263Da peak is also a fragment of fibrinopeptide A.  
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3.3.3 MALDI-TOF Pattern Analysis of Other Sample Sets 
Sample collection and preparation have proved to be essential for human 
serum proteomic research [Hsieh et al., 2006]. A standardized sampling procedure 
was suggested for proteome comparison and biomarker discovery. For samples 
collected years ago from different institutions, it is very hard to follow this 
recommendation. So, after validation of efficacy of the method and the identification 
of the marker peaks using the first GOG bank sample sets, we further tested the 
ovarian cancer marker (1465Da/1260Da >2) on other new sample sets.  
The first sample set is from Cooperative Human Tissue Network – University 
of Pennsylvania Medical Center. This sample set consists of 19 normal serum samples. 
One of them was from male donor and therefore being excluded from this study. 15 
out of 18 samples (~83%) didn’t show any marker peak within the 1200-1600Da mass 
range using MALDI-TOF pattern analysis. Among the 3 samples which have 
detectable marker peaks, 2 of them can be classified as normal (1465Da/1260Da <2), 
only one sample showed false cancer-positive signal (1465Da/1260Da = 4.64). The 
discrepancy observed could be a result of different sample preparing procedure. But 
since low overall marker peak intensity is also an important observation in the first 
GOG tissue bank normal sample set (no marker peaks were detectable in one of those 
samples), we decided to add another distinguishing factor - no marker peaks 
detectable (or 1465Da/1260Da =1) - to our marker list for classifying normal samples. 
And with this 2 classification factors, we identified 35 out of 36 normal samples 
correctly. 
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The second sample set is from GOG tissue bank - Columbus Children 
Research Hospital. While the first set of GOG tissue bank samples we used were all 
collected in year 2003, this second sample set contains samples dated back to 1993 
and most of them (41 out of 60) were collected before year 2000. This sample set 
contains 40 various carcinoma samples and 20 benign samples in 3 pathological 
categories. The MALDI-TOF pattern analysis resulted in a 97.5% (39 out of 40) 
sensitivity for carcinoma samples and 85% (17 out of 20 ) for benign samples when 
using 1465Da/1260Da >2 as marker. There was no significant difference between 
different types of benign and carcinoma samples. But the average level of marker 
value was notably elevated from benign to carcinoma. Two sample t-test also proved 
significant differences between normal, benign, and cancer sample sets (data not 
shown). Detailed statistical analysis was summarized in Table 3.1 and Table 3.2.  
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Table 3.1 Statistical analysis of ovarian cancer marker: 1465Da/1260Da 
 
 
PA  
Normal 
GOG  
Normal 
Normal 
All 
Benign 
 
GOG 
Cancer 1 
GOG 
Cancer 2 
GOG Cancer 
All 
Mean 1.15 0.60 0.87 13.74 56.64 49.95 52.18 
SD*** 0.90 0.30 0.72 13.97 37.79 36.09 36.48 
SE*** 0.21 0.07 0.12 3.12 8.45 5.71 4.71 
Min 0.11 0.20 0.11 0.94 0.49 3.27 0.49 
Max 4.64 1.10 4.64 57.59 100.00** 100.00** 100.00** 
Median 1.00* 0.57 1.00* 8.65 49.28 40.74 41.90 
N 18 18 36 20 20 40 60 
 
* Marker ratio was manually set to “1” if no marker peaks detectable in normal 
samples 
** Marker ratio was manually set to “100” if marker ratio is larger than 100 in cancer 
patient samples. 
*** SD – Standard Deviation, SE – Standard Error 
 
 
 
Table 3.2 Elevated marker level correlated to cancer development 
  Normal Benign Carcinoma 
1465Da/1260Da>2 1/36 (2.8%) 17/20 (85%) 55/60 (91.7%) 
1465Da/1260Da>10 N/A 9/20 (45%) 49/60 (81.7%) 
1465Da/1260Da>20 N/A 5/20 (25%) 40/60 (66.7%) 
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3.4 Conclusive Remarks 
In this project, we have demonstrated a novel organic precipitation method 
coupled with enzymatic deglycosylation to extract cancer related markers from low 
molecular weight portion of human serum proteome. Several marker peaks were 
robustly detected and validated in different clinical sample sets. The identification of 
these markers was determined by tandem mass spectrometry coupled with database 
searching. Interestingly, most of the major peaks detected were derived from 
fibrinopeptide A – a product of thrombin induced fibrinogen activation. 
Fibrinogen is the main protein of blood coagulation system. It is a large 
protein (MW 340 kDa) in human and it consists of two identical subunits that contain 
three polypeptide chains: α, β and γ. Fibrinopeptide A (1 – 16 amino acids) and B (1 – 
17 amino acids) are released by thrombin from the N terminal parts of α- and β-chains, 
respectively. In this way fibrinogen is converted into fibrin, which forms a fibrin clot 
by polymerization [Maurer et al., 2000]. Pathological hemostasis activation often 
occurs in cancer patients [Wojtukiewicz et al., 2000]. And the presence of fibrin in 
and around tumors may be essential for tumor growth [Zacharski et al., 1990]. While 
there is no direct correlation between plasma FPA levels and plasma fibrinogen 
concentration, extravascular metabolism of fibrinogen and formation of fibrin in or 
around tumor may account for the leakage of FPA into the circulation [Wilner et al., 
1978] and therefore responsible for abnormally elevated circulating FPA levels.  
A correlation between elevated plasma level of FPA and ovarian cancer was 
reported previously [Gadducci et al., 1994]. Using competitive enzyme-linked 
 65
immunoassay (cELISA) to measure FPA levels, they have achieved very high 
specificity (100%) and fair sensitivity (64%) in distinguishing ovarian carcinoma 
patients from benign or controls. But they also concluded that there was no difference 
in FPA level between benign and controls. The antibody used in cELISA is able to 
capture all FPA related fragments as long as they still contain the recognition site. 
This will limit the differentiation power when there are metabolic fragments hanging 
around. In our study, the application of MALDI-TOF MS pattern analysis provided an 
accurate tool of measuring interested molecules. The real cancer related molecule 
could be well distinguished from others. Much higher sensitivity and the capability of 
distinguishing benign ovarian diseases from controls and cancer patients were two 
major benefits. The mechanism of high level des-alanine fibrinopeptide A and its 
correlation with ovarian cancer is still unknown. Orvisky and colleagues reported a 
down-regulated serum des-alanine FPA level in hepatocellular carcinoma [Orvisky et 
al., 2006]. This observation indicated that the level of circulating des-alanine 
fibrinopeptide A is cancer pathology specific and more research should be done to 
elucidate the mechanism. 
As an additional procedure before MALDI-TOF pattern analysis, enzymatic 
deglycosylation proved to be critical for signal clean up and quantification. 
Peptide-N-glycosidase F (PNGase F) is one of the most widely used enzymes for the 
deglycosylation of glycoproteins. The enzyme releases asparagine-linked (N-linked) 
oligosaccharides from glycoproteins and glycopeptides, and the substrate could be as 
small as a tripeptide (Asn-Xaa-Ser/Thr, where X can be any amino acid, except Pro). 
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The removal of glycans was especially beneficial in normal samples which generate 
much less abundant signals and are readily to be affected by suppression effects (data 
not shown). The identity of 1260Da marker peak should be further studied, and it’s 
highly probable to be a glycopeptide (see Figure 3.3). 
As a conclusion, we have developed a novel organic solvent precipitation 
method for separating and enriching low molecular weight species from human serum. 
An enzymatic deglycosylation step was used before MALDI-TOF MS pattern 
analysis to improve data quality and marker quantification. Elevated circulating 
Des-alanine fibrinopeptide A level was found to have correlation with development of 
ovarian cancer. The whole procedure is simple and the results are exiting. 
Preoperative plasma may be a better sample system for validating markers found in 
this study. More clinical samples sets should be tested with standardized collecting 
and preserving protocols. 
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ANALYSIS 
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CHAPTER IV 
GENERAL INTRODUCTION 
 
 
 
4.1 Single Nucleotide Polymorphisms (SNPs) Detection 
4.1.1 What are Single Nucleotide Polymorphisms (SNPs)? 
Single Nucleotide Polymorphisms (SNPs) are single base substitutions that 
occur at a specific position in a genome (Figure 4.1.1a). Single-base insertions and 
deletions are not strictly SNPs, but they are often included under this genetic 
definition (Figure 4.1.1b). In general, the rare (less frequent) allele has an abundance 
of 1% or greater in a population, otherwise it is referred to as point mutation [Brookes, 
1999]. In diploid species as humans, SNPs are usually biallelic (a SNP has two alleles 
and three or four alleles are very rare). Averagely speaking, one SNP could be found 
every 300 to 1000 bases in humans. They are estimated to represent as much as 90% 
of all genetic variations [Cooper et al., 1985].  
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Figure 4.1.1 (a) The two alleles of a single nucleotide polymorphism; (b) a single 
nucleotide deletion/insertion. 
 
 
 
 
 
 
 
 80
1.42 million SNPs were reported [Sachidanandam et al., 2001] and now there are 
more than 6 million mapped human SNPs in public databases [Collins et al., 2003]. 
Only a small portion of located SNPs lie within coding regions (cSNPs) and an even 
smaller percentage will result in sequence changes in expressed proteins. However, 
non-coding SNPs can still influence mRNA stability and conformation, as well as the 
quantity and quality of gene expression product. To geneticists, it is highly valuable if 
a marker can be pinpointed directly in the genomic region of interest. An allele of a 
SNP can be an important genetic risk factor as it may increase susceptibility to certain 
diseases. Due to their biallelic nature, SNPs are fairly easy to detect in genotyping and 
data interpretation can be automated.  
 
4.1.2 Genotyping SNPs Using MALDI-TOF Mass Spectrometry 
Numerous approaches have been developed in genotyping SNPs. Criteria 
such as accuracy of SNP detection, sensitivity to identify SNPs using a small amount 
of template, throughput, and flexibility of the procedure were thoroughly explored. 
Traditional methods based on molecular biology techniques often lack essential 
features for clinical settings such as accuracy, automation, and throughput. In terms of 
robustness, accuracy, reproducibility, and success rates, mass spectrometry assays 
based on primer extension reactions surpassed most other methods in side by side 
comparison [Le Hellard et al., 2002].  
All methods for SNP genotyping combine two fundamental steps: the 
generation of an allele-specific product, and the analysis thereafter. Currently, four 
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major methodologies are used for the generation of the allele-specific products: 
hybridization, ligation, cleavage, and primer extension. All of these methods for allele 
discrimination have been combined with MALDI-TOF analysis [Tost and Gut, 2005]. 
The most widely applied method for allele distinction in SNP genotyping and point 
mutation analysis is primer extension [Syvänen et al., 1990]. Several types of primer 
extension assays using MALDI-TOF MS as the detection platform have been 
developed. Differentiation of the alleles is basically achieved by three different 
strategies: single base primer extension (SBE), multiple base primer extension, and 
nucleotides depletion. Each extension product of a SNP is detected based on their 
mass differences. In single base primer extension, this is due to the addition of 
nucleotides that naturally differ in mass, and in multiple base primer extension, the 
addition of a different number of bases will distinct alleles.  
For single base primer extension (SBE) reaction, the primer anneals 
immediately next to the polymorphic site and terminating dideoxynucleotides 
(ddNTPs) were used in extension reaction. Therefore, unlike in regular PCR reaction, 
the primer is only extended with a single nucleotide. This approach is applied in the 
PinPoint assay [Haff and Smirnov, 1997], and commercialized by Applied Biosystems 
as the SequazymeTM PinPoint SNP Typing Kit. The reaction procedure is outlined in 
Figure 4.1.2.  
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Figure 4.1.2 The reaction procedure of the PinPoint assay [Haff and Smirnov, 1997]. 
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The GOOD assay was introduced by Sauer and colleagues [Sauer et al., 
2000a,b]. Utilizing a chemical modification strategy – charge tagging [Gut et al., 
1997], this assay doesn’t require purification step prior to MALDI analysis. It reduces 
the extension products to a core-sequence of four to five nucleotides that contain the 
allele information by enzymatic digestion and could increase signal intensity to up to 
100 fold.  
Other methods like the solid phase capturable single base extension 
(SPC-SBE) assay [Kim et al., 2002] and the genoSNIP assay [Wenzel et al., 2003] are 
also based on single base primer extension principle. The SPC-SBE assay 
distinguishes itself from other assays by using biotinylated ddNTPs and only extended 
products are retained on target. Non-extended primers were eliminated and therefore 
increased the possibility of multiplexing. The genoSNIP assay is characterized by 
using photocleavable primers.  
Since the smallest mass difference between two nucleotides (A and T) is only 
9 Da, analysis of some SNPs may be difficult by SBE assays. To enhance the allele 
distinction in the mass spectrum, a mixture of deoxynucleotides (dNTPs) and 
dideoxynucleotides (ddNTPs) were used in multiple base primer extension principle. 
The primer anneals again immediately adjacent to a SNP site, one allele is extended 
by only one base (ddNTPs) while the second one by two or more (termination occurs 
at the first nucleotide in the template complementary to a ddNTP). This strategy could 
generate extension products with a mass difference of at least 300 Da. With enhanced 
allele discrimination, this concept is used in the primer oligo base extension (PROBE) 
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assay [Braun et al., 1997], the MassEXTEND assay [Leushner and Chiu, 2000] 
(Sequenom), and the very short extension (VSET) assay [Sun et al., 2000]. A 
schematic representation of PROBE assay is shown in Figure 4.1.3.  
The MassEXTEND assay is an improved version of the original PROBE 
assay. It uses ion-exchange resin for sample conditioning, avoided biotinylated 
primers and immobilization as used in the PROBE assay. Extremely small volumes 
(nanoliter) of samples are transferred onto silicon target pre-spotted with 
3-hydroxypicolinic acid (HPA) matrix. As the entire sample spot is volatilized with a 
few laser pulses, the need for searching sweet spots of the HPA matrix is avoided. 
The very short extension (VSET) assay was designed to address some of the 
problems associated with both the original PinPoint and the PROBE assay. In contrast 
to the original PROBE assay, three ddNTP and one dNTP were used in primer 
extension reaction. As a result, for one allele, extension is one base and for the other 
are two bases, which separates the alleles by a mass of about 300 Da.  
Nucleotide depletion genotyping assay (NUDGE) is essentially a variant of 
multiple base primer extension strategy. This method was reported by Decode 
Genetics recently [Blondal et al., 2003] and the primer is designed to anneal two bases 
upstream of the polymorphic site. The allele is discriminated in the presence of only 
three deoxynucleotides. The one that is complementary to one allele of the SNP is 
depleted. Therefore, termination occurs right next to the polymorphic position for one 
allele, while for the other allele, extension will not stop until the first nucleobase in 
the template complementary to the depleted dNTP.  
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Figure 4.1.3 The PROBE assay [Braun, Little and Köster, 1997]. The biotin-label is 
shown as a black circle, which is captured in streptavidin-coated microtiter plates. 
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However, analysis of nucleic acids by MALDI mass spectrometry has some 
drawbacks. MALDI-TOF mass spectrometry is very sensitive to the presence of metal 
ions. Due to the multiple negatively charged sugar phosphate backbone of DNA 
molecule, it is susceptible to form adduct with common cations such as Na+ and K+. 
Peak broadening and reduction of resolution, sensitivity and accuracy are direct 
consequences of adduct formation. As cations such as sodium and potassium are 
highly abundant in buffers for molecular biology reactions, stringent purification 
procedures need to be applied. Approaches to overcome adduct formation are mostly 
based on ion-exchange principles. This could be done either on solid-phase [Tang et 
al., 1995] or through cation-exchange resin methods [Nordhoff et al., 1992]. The 
addition of ammonium containing organic modifiers to the matrix reduces 
heterogeneity of oligonucleotide ions caused by cation adducts. The ammonium is 
volatile and could be dissociated from the analyte molecules during laser pulse 
bombardment, and therefore leaving the analyte in free acid form. Diammonium 
citrate and tartrate are reported to be good choices serving this purpose [Pieles et al., 
1993; Lecchi and Pannell, 1995]. 
The other drawback for MALDI-TOF mass spectrometry lies in the sample 
deposition method. The standard method for sample preparation is called 
dried-droplet method. In this method, a small drop (usually about 0.5µL) of sample 
solution is applied on a drop of prepared matrix solution (usually about 1µL) and 
allowing the mixture to dry. During the crystallization of matrix, analyte molecules 
were also redistributed and “sweet spots” were formed. The existence of 
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heterogeneous “sweet spots” will reduce the sensitivity and accuracy when applying 
MALDI-TOF in SNP analysis. Nanoliter liquid deposition technology was used to 
overcome “sweet spots” formation, but this will greatly limit the quantity of analyte 
loaded.  
Choices of matrices, combination of sample conditioning prior to mass 
spectrometry analysis and sample preparation are all essential components of 
successful analysis of SNPs using MALDI-TOF mass spectrometry. Novel strategy is 
always needed and being continuously developed to improve the sensitivity, accuracy, 
and cost effectiveness of mass spectrometry based genotyping.  
 
4.2 Microsatellite Instability Detection 
4.2.1 Microsatellite Instability and Cancer 
Microsatellites are one of the most abundant classes of intergenic repetitive 
sequences dispersed in the eukaryotic genome and contain repetitive units composed 
of one to five base pairs [Weber et al., 1989; Litt et al., 1989; Dib et al., 1996]. These 
sequences, as well as minisatellite sequences, are highly polymorphic in human 
populations and could be used as a marker for human identification or pedigree 
analyses [Hearne et al., 1992]. During the progress of the Human Genome Project, 
numerous microsatellite loci have been pinpointed on the human genome and are now 
being used for various genomic analyses.  
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Figure 4.2.1 (A) Normal replication event of MS DNA; (B) strand slippage event 
initiating an abnormal replication; (C)effective repair leading to normal replication 
(A=C); (D) defective repair of B leading to microsatellite instability (A≠D). [Samara 
et al., 2006] 
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Compared with other regions on the genome, these repetitive sequences were 
thought to be stable within the life span of organisms. However, microsatellites are 
mainly located in non-coding regions (introns) of genome. Due to their repetitive 
characteristics, they are likely to be the site of insertion and deletion mutations during 
DNA replication, with an error rate of 1 in 100,000 base pairs copied. The majority of 
these errors could be detected and corrected by the inherent proof reading capabilities 
of DNA polymerases. A small proportion of mismatches that are missed by this 
mechanism are normally identified and corrected by a group of proteins named the 
mismatch repair (MMR) system [Fishel, 1999]. Dysfunction of the MMR system 
allows the accumulation of replication errors and leads to microsatellite instability 
[Strand et al., 1993], which could be defined as “a change of any length due to either 
insertion or deletion mutations of repeating units in a microsatellite" [Boland et al., 
1998]. A representative scheme of MSI is shown in Figure 4.2.1. 
Microsatellite alterations can be found in a number of tumors. There are two 
types of alterations: loss of heterozygosity (LOH), which can be detected in the 
majority of colorectal cancers (CRC), and microsatellite instability (MSI). Instability 
of a class of microsatellites with dinucleotide repeats was initially reported in 
colorectal cancer [Thibodeau et al. 1993; Ionov et al., 1993; Aaltonen et al., 1993] and 
in patients with hereditary non-polyposis colorectal cancer (HNPCC) [Peltomaki et al., 
1993]. Because mutations in genes functioning in DNA mismatch repair were found 
to be inherited in pedigrees of HNPCC, microsatellite instability was regarded as an 
important phenotype of deficiency in DNA mismatch repair and as a marker of a high 
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risk for cancer. High-degree microsatellite instability (MSI-H) is a feature of most 
colorectal cancers arising as part of the hereditary non-polyposis colorectal cancer 
(HNPCC) as well as 15–20% of sporadic colorectal cancers [Haydon et al., 2002]. 
And it was reported that all colorectal cancers display some degree of microsatellite 
instability if enough markers are studied [Umar et al., 2004].  
As a potential marker, MSI were also investigated in other cancers. The 
results are rather contradictory, though. For example, Mao and colleagues [Mao et al., 
1994; 1996] observed high frequency microsatellite instability in transitional cell 
carcinoma (TCC) of bladder with both tumor DNA and DNA extracted from urine. 
But other researches demonstrated much lower frequency, or lack of correlation in 
TCC pathological data with MSI [Catto et al., 2004].  
Siah and colleagues reported low detection rate of MSI in early-onset breast 
cancer patients [Siah et al.; 2000]. Two of the most recommended MSI marker, 
BAT-25 and BAT-26, failed to show any MSI in tumor DNA. While Wild and Murata 
all reported successful detection of MSI with a relatively higher detection rate [Wild 
et al., 2000; Murata et al., 2002]. 
The discrepancy of results could be greatly related to the experimental design. 
Choices of markers, sources and handling of clinical samples, researchers’ standard of 
MSI categorization and MSI detection methods can all be distinguishing factors 
among studies. More work should be done to develop accurate and objective assay 
systems so that the clinicopathologic features of microsatellite instability could be 
revealed. 
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4.2.2 Microsatellite Instability Detection 
4.2.2.1 Markers for Detecting Microsatellite Instability 
In 1997, an International Collaborative Group announced guidelines for the 
identification and assessment of microsatellite instability [Boland et al., 1998]. They 
classified tumors into microsatellite stable (MSS) and two groups of microsatellite 
unstable cancers based on their degree of instability: high (MSI-H) or low (MSI-L). 
BAT-25 and BAT-26, two mononucleotide microsatellite markers, and three 
dinucleotide markers (D2S123, D5S346 and D17S250) were chosen as a panel to be 
studied for determining MSI status. Tumors displaying instability in two or more 
markers were designated MSI-H, instability in only one marker was designated 
MSI-L and if no markers were affected the tumor was designated MSS. There is now 
a growing consensus that the pathological phenotype of MSI-H is characterized 
particularly by instability in the mononucleotide markers [Umar et al., 2004]. 
Colorectal cancers with MSI-H demonstrated unique biological behavior while MSI-L 
cancers are less well characterized and are often grouped with cancers that are 
categorized as MSS [Gonzalez-Garcia et al., 2000]. 
More and more markers were tested in different research approaches. It was 
generally proved that the detection efficiency could be improved using expanded 
marker panels. And besides the mono- and dinucleotide markers originally defined on 
the NCI workshop, markers with longer sequence instability (tetranucleotide repeats, 
for example) demonstrated some advantages in cancer detection [Catto et al., 2003]. 
The hMLH1 promoter region was reported to be highly methylated in about 80% of 
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microsatellite instability MSI (+) colorectal cancers, but in none of the MSI (-) 
colorectal cancers [Masato Maekawa et al., 1999]. The correlation between hMLH1 
gene hypermethylation and MSI was also reported in T cell lymphoma [Scarisbrick et 
al., 2003]. These findings could be a good lead to the pathological features behind 
MSI. 
 
4.2.2.2 Methods for Microsatellite Instability Detection 
Usually, a set of microsatellite markers is amplified by PCR followed by gel 
or capillary electrophoresis to separate PCR amplicons. Various detection method 
have been applied to illustrate the markers amplified, such as autoradiography 
[Thibodeau et al, 1993], silver staining [Schlegel et al, 1996], or fluorescence 
techniques [Gyapay et al, 1996]. The representative results using different methods 
are shown in Figure 4.2.2 and Figure 4.2.3. 
Autoradiography method is using radiolabeled (32P) oligonucleotide primers 
during polymerase chain reaction (PCR). The amplified products are electrophoresed 
on a sequencing gel and visualized using X-ray developed films. Silver stain is an 
alternative band visualization method for polyacrylamide gel electrophoresis (PAGE) 
without involving radioactive isotopes. Both methods suffer the known disadvantages 
of PAGE, such as migration error, low sensitivity and cumbersome procedures. 
Newly developed fluorescence based sequencing method could overcome all 
problems mentioned above [Oda, et al., 1997].  
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Figure 4.2.2 A representative example (case #28) of microsatellite instability in 
gastric cancers (radioactive electrophoresis method). T: tumor samples; and N: 
corresponding normal samples. Microsatellite markers are shown on the top of the 
gels. Bands of abnormal size are detected in all tumor lanes of case #28 [Yamada et 
al., 2002]. 
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Figure 4.2.3 Variation of MSI profile among different regions in MSI tumors. 
Amplification of D2S123 microsatellite in 3 different regions of case 109. This is a 
homozygote marker with 1 normal allele of 121 bp. Three unstable alleles are 
amplified in region A, only 1 in region B, and 2 in region C [Danjoux et al., 2006]. 
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The separation power of capillary electrophoresis combined with high 
throughput automated instrumental design could make fluorescence based sequencing 
a standard routine for MSI analysis. 
Other than the widely adapted strategies, researchers have applied newly 
developed technologies in MSI analysis and cancer detection. Dietmaier and 
colleagues have established a technique to detect MSI by LightCycler Real-time PCR 
and melting point analysis [Dietmaier et al., 2001]. Amplification of microsatellites 
by real-time PCR is followed by melting point analysis to display alterations in the 
length of repetitive sequences. According to their results, amplification and melting 
point determination of BAT26 and BAT25 was achieved in 129/162 (80%) and 
123/162 (76%) formalin-fixed and paraffin-embedded tissue samples, respectively. 
Moreover, MSI could be detected only in MSI-high tumors using both BAT25 and 
BAT26 markers. This new technique allows MSI detection within 1 hour and 
provides an alternative way for fast, high-throughput MSI analysis. 
Denaturing high-performance liquid chromatography (DHPLC) was 
compared side by side with fluorescence capillary electrophoresis (FCE) in MSI 
detection [Deschoolmeester et al., 2006]. Developed by a Korean group in 2003 [Kim 
et al., 2003], this method was proved to be as effective as FCE on quasimonomorphic 
BAT markers, but hard to interpret for the detection of dinucleotide markers. 
Clinicopathologic features of microsatellite instability positive cases have 
remained unclear. Introducing automated sequencer for microsatellite assay was a 
breakthrough for MSI analysis and cancer detection. The use of dual 
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fluorescence-labeled primers and an automated sequencer is recommended for 
accurate detection. However, to improve MSI detection using highly complicated 
clinical samples other than malignant tissues, novel sample preparation and PCR 
strategy has to be developed. 
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CHAPTER V 
MATRIX-ASSISTED LASER DESORPTION/IONIZATION 
TIME-OF-FLIGHT ANALYSIS OF LOW-CONCENTRATION OF 
OLIGONUCLEOTIDES AND MINI-SEQUENCING PRODUCTS 
 
 
 
5.1 Introduction 
The genotyping method based on matrix-assisted laser desorption/ionization 
time-of-flight mass spectrometry (MALDI-TOF MS) is one of the most promising 
approaches to large scale genotyping of single nucleotide polymorphisms (SNPs) 
[Braun et al., 1997a,b; Haff et al., 1997a,b; Hihhins et al., 1997; Little et al., 1997a,b,c; 
Fei et al., 1998; Fu et al., 1998; Ross et al., 1998; Chen et al., 1999; Griffin et al., 
1999; Li et al., 1999; Sun et al., 2000], as MALDI-TOF is fast, provides higher 
accuracy in molecular weight data, and requires no fluorescent or radioactive labeling. 
However, these advantages are somewhat not match well to mini-sequencing, the 
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most widely used sequencing reaction employed in genotyping. This is evident by the 
fact that the overall detection limit of a MALDI-TOF based genotyping method is 
significantly poorer than that of fluorescent-based detection, though MALDI-TOF 
itself is extremely sensitive. The poor detection limit leads to a significant increase in 
genotyping costs and difficulty in designing multiplexed assays. 
This mismatch is due to the fact that, unlike other methods, MALDI utilizes a 
very small portion of sequencing products for data acquisition. In MALDI, each laser 
shot targets a spot of ~100μm2. In general the MALDI sensitivity is, to a large extent, 
dictated by the amounts of the analyte present on the targeted spot, rather than total 
quantities loaded. In other words, the more analytes that are present on the targeted 
spot, the higher the sensitivity will be. Conventional methods use a metal sample 
substrate. The aqueous solution of 3-HPA/DNA tends to spread to a large area on the 
metal surface as a result of strong interactions between metal and polar solvents. For 
example 0.5μL of aqueous solution can spread to an area of 1.5 mm in diameter. The 
formation of a large-area sample inevitably reduces the oligonucleotide quantity in a 
targeted spot, thus reducing sensitivity. Clearly, an ideal sample preparation method 
should deposit most, if not all, of the mini-sequencing products onto a target, and 
more importantly it should produce the smallest possible sample area so that the 
deposited molecules can be maximally assessed by the same laser shot. Other 
essential requirements for a good sample preparation method include good sample 
homogeneity for fast automatic data acquisition, and good sample-to-sample and 
spot-to-spot reproducibility for quantitative analysis. 
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Recently, we reported a shrinkage strategy in which a hydrophobic surface 
was used as the sample substrate [Hung et al., 1998]. The hydrophobic nature of the 
sample substrate forces the aqueous drop to shrink to a small area thereby 
concentrating analyte molecules on target. More recently, Nordhoff and coworkers 
extended this method by adding a small hydrophilic spot, which acts as an anchor that, 
if touched, holds the sample droplet and directs crystallization onto it [Schuerenberg 
et al., 2000]. Two sample loading procedures have been investigated. The first one 
shrinks the matrix solution first, followed by adding the DNA solution onto the top of 
the dried matrix film [Hung et al., 1998; Huang et al., 1999]. The second procedure 
shrinked the aqueous solution containing both matrix and analyte [Schuerenberg et al., 
2000]. These methods work well when applied t analysis of high-concentration 
oligonucleotides, but did not work well with low-concentration oligonucleotides, at 
least in our hand, in terms of sensitivity and reproducibility. In addition, both 
procedures involve the shrinkage of the solution containing the matrix on a 
hydrophobic surface, but it is difficult to control the shrinkage of the aqueous 3-HPA 
solution. It was observed that if too much matrix was loaded, much larger sample 
areas were formed. If too little matrix was loaded, the sample quality is poorer. 
In this work, we developed a new procedure in which a few μL of the 
oligonucleotide solution are first deposited on the target, followed by addition of a 
small volume (0.1μL) of saturated 3-HPA solution. It is seen that this procedure is 
superior to existing procedures, and can substantially improve the MALDI sensitivity 
and sample homogeneity. The application of this procedure on low-concentration 
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oligonucleotides and mini-sequencing products showed that the detection limit and 
data robustness were greatly improved. 
 
5.2 Methods and Materials 
Oligonucleotides were purchased from MWG Biotech Inc.(High Point, NC, 
USA). 3-Hydroxypicolinic acid (3-HPA), diammonium citrate, and NH4+ 
ion-exchange beads were obtained from Aldrich (Milwarkee, WI, USA). All samples 
were used without further purification. The saturated 3-HPA matrix solution was 
prepared in 50 mM diammonium citrate solution containing 25% (v/v) of acetonitrile. 
Stock DNA solutions were prepared in water. The concentration of the DNA solution 
was determined by UV absorption measurements. The DNA mixture solutions were 
prepared prior to loading them on the sample tip. 
All mass spectra were collected using OmniFlexTM MALDI-TOF mass 
spectrometer (Bruker, Bilerica, MA, USA) operated in the linear, negative mode, 
delayed extraction has been turned on. OmniFlexTM uses a 337-nm pulsed nitrogen 
laser which has a duration of 3ns and a full power of 175μJ. Our experiment was 
typically carried out at about 78% of full laser power with 600 ns delay extraction and 
9.3kV ion focus voltage. This laser power was slightly higher than that used when 
samples were prepared by conventional methods. Sampling rate is 2Hz. The sample 
target was a 400μm, 6 x 6 anchorchipTM abtained from Brucker. If not specified, 
otherwise, 2 μL of oligonucleotide solution were first deposited on the anchorchipTM, 
followed by dispensing 0.1μL of the saturated 3-HPA matrix solution. All sample 
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spots were searched manually to locate the “sweet” spots. 
 
5.3 Results and Discussion 
5.3.1 Sample Preparation 
The first series of experiments was performed to determine the best sample 
preparation conditions. The sample target used was a 400μm anchoring chip which is 
coated with a thin film of Teflon-like hydrophobic material and carries a 400μm 
hydrophilic center. The selection of anchoring chips over a pure hydrophobic center is 
based on the observation that the sample solution tends to form a dried spot on the 
hydrophilic surface, allowing the use of an automatic liquid handling system to 
precisely deposit a small volume of matrix onto the top of a dried sample spot without 
visualization.  
The key to this procedure is to confine all deposited samples to the 
hydrophilic surface. It was seen that the addition of a small amount of diammonium 
citrate to the oligonucleotide solution could facilitate the shrinkage of a aqueous 
solution on an anchoring chip and reduce the salt effects. The diammonium citrate 
solution was normally treated with NH4+ ion-exchange beads before being added to 
the oligonucleotide solution. In general, the sample solution contained 0.001M of 
diammonium citrate if the oligonucleotide concentration was 0.01 μM or higher. 
When lower concentration samples were analyzed, the amount of diammonium citrate 
should accordingly be reduced. In this work, we manually dispensed both 
oligonucleotide and matrix solutions to the sample target. Therefore, care was taken to 
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deposit the sample solution onto the center of the anchoring spot. Otherwise, the 
sample solution may not be confined to the hydrophilic center. In the same way, great 
care was taken to deposit a small drop of the matrix solution onto the top of the 
shrunk DNA spot. We found that the result was poorer if the matrix was not deposited 
on the top of the sample spot. An automated liquid handling system should be used 
when a large number of samples are prepared by this method, as this will eliminate 
the potential human error during sample preparation. 
We investigated the matrix concentration effect using the matrix solution at 
three different concentrations. In all three cases, 0.1 μL of the 3-HPA solution was 
loaded. We observed that the sample sizes created from these three solutions were 
similar, but the more diluted the 3-HPA solution was, the thinner the 3-HPA film was 
formed. The diluted solution tended to form a 3-HPA film containing many thin 
needle-like threads. In contrast, the saturated solution produced many thin threads 
surrounded by small crystals across the entire sample. Interestingly, it was the 
saturated 3-HPA solution that gave the best results in terms of sensitivity, 
homogeneity, and reproducibility. We also investigated the effect of CH3CN and 
observed the similar results when the CH3CN concentration was 25-50%. Higher 
concentration of the CH3CN will interfere with the shrinking process. The results 
indicated that the careful selection of CH3CN combined with saturated 3-HPA yields 
better matrix/sample co-crystals and more uniform samples (less gaps between crystal 
threads), improving the sampling efficiency. Therefore, the saturated 3-HPA solution 
prepared in 25% of CH3CN was used throughout this experiment. In general, the 
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sample size formed by this procedure is about 0.4-0.6 mm. 
 
5.3.2 Sensitivity and Homogeneity 
Figure 5.1 shows typical MALDI-TOF mass spectra of equal molar 
oligonucleotide mixtures containing either 16/17 or 24/25 mers. The samples were 
prepared by loading 2 μL of the mixture solution, followed by the addition of 0.1 μL) 
of the saturated 3-HPA solution to the dried oligonucleotide spot. The concentration of 
each oligonucliotide mixture was ~0.01 μM (Figure 5.1(a) and 5.1(c)) and ~0.002 μM 
(Figure 5.1(b) and 5.1(d)), respectively. As seen from Figure 5.1, all four 
oligonucleotides were detectable at concentrations of 0.01 and 0.002 μM. However, at 
0.01 μM, little efforts were needed to search for ‘sweet’ spots, while some searching 
efforts were required if the concentration was reduced to 0.002μM. A similar 
sensitivity was obtained with many other oligonucleotides including one 30 mer. It 
should be noted that no attempt was made to determine the uppermost sensitivity of 
this procedure as we were more interested in determining the lowest DNA 
concentration at which we could produce homogenous and reproducible samples, 
since these factors are equally important to genotyping of SNPs. Therefore, we 
evaluated this new procedure at the oligonucleotide concentration of 0.01 μM or 
higher in the rest of this work. 
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Figrue 5.1 MALDI-TOF mass spectra of equal molar oligonucleotide mixtures of 
16/17- and 24/25mers obtained at concentrations of 0.01µM ((a) and (c)) and 
0.002µM ((b) and (d)). 
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It was observed that the sample size could be further be further reduced, as 
the sample size was dictated by the volume of matrix. At present, it is difficult for us 
to load less than 0.1 μL of solutions with a standard syringe or pipetter. However, a 
piezoelectric microdispenser can deposit as little as 10 nL of a solution on target 
[Little et al., 1997; Miliotis et al., 2000]. It is anticipated that the use of a piezoelectric 
microdispenser might further improve the sensitivity of this new procedure. 
The ability of rapid screening of a large number of samples is essential to 
high-throughput genotyping. A series of experiments with a mixture of 16- and 17 
mers at 0.01 μM was conducted to evaluate the application of this procedure to a 
high-throughput operation. First, we examined the signal duration on a given spot to 
see whether a good spectrum can be generated just from a single targeted spot. Figure 
5.2 displays three spectra collected from the first 30 shots, second 30 shots, and third 
30 shots from the same targeted spot, respectively. In most of the cases, strong ion 
signals were still observable even after 70 laser shots if the laser power was kept at 
the level that was slightly higher than threshold. Importantly, it was seen that good 
signal-to-noise (S/N) peaks could be robustly generated just from a single spot. The 
good signal duration and quality allow acquisition of a good spectrum from one spot 
instead of multiple spots, thereby avoiding the need to search for additional spots. It 
should be noted that, in some cases, there were no oligonucleotide ion signals or 
signals were much weaker during the first few laser shots. However, the signals 
actually increased significantly after a few laser shots. This suggests that 
oligonucleotides distributed from the top surface to the interior part of the 3-HPA film 
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and that long signal duration may result from the formation of a thicker 3-HPA matrix 
film. 
The sample homogeneity was further examined by preparing samples in an 
identical manner, followed by collecting one good spectrum from each of 36 wells. In 
this experiment, we intended to determine how many sample spots should be searched 
randomly to find a ‘sweet’ spot. An S/N ratio of 5 was used to accept or reject the 
spectra. If the S/N ratio was equal to or better than 5, no more searching was 
performed. Otherwise, more spots were searched until a good spectrum was collected. 
In this experiment, the ‘sweet’ spots were searched manually. We found that all 36 
samples produced the similar high-quality spectra and that the average number of the 
spots searched was 2-3. For example, Figure 5.3 displays the typical spectra obtained 
from sample targets 3, 7, 16, 24, 28 and 35, respectively. Moreover, we observed that 
high-quality spectra could be produced across the entire sample. This result clearly 
indicated that the samples prepared by this new procedure are highly homogenous and 
therefore it is suitable for high-throughput DNA analysis. 
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Figure 5.2 Typical MALDI-TOF mass spectra obtained from the first 30 shots, 
second 30 shots, and third 30 shots. 
 
 
 
Figure 5.3 Representative MALDI-TOF spectra obtained from 36 sample spots 
prepared in an identical manner. The spectra shown were obtained from spots 3, 7, 16, 
24, 28, and 35. 
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5.3.4 Reproducibility and Quantitative Analysis 
One other issue related to genotyping of SNPs is the determination of the 
frequency of each of the two alleles when a pooling sample of many people is 
analyzed. Therefore, we also evaluated this procedure for its applicability in 
quantitative analysis of two oligonucleotides which are different by one base. The 
objective of this evaluation was to determine how many people could potentially be 
pooled together for an accurate determination of the allele frequencies. In this 
experiment, six samples were prepared in an identical manner, and five spectra were 
collected from five different positions from each of the six samples. The sample 
mixture used contained 0.04 μM of 16- and 17 mers. Table 5.1 lists the signal 
intensity ratios of the 16- and 17mer peaks from each of the 30 spectra. These peak 
intensity ratios were calculated based on the peak aera including the area of the salt 
adduct peaks. It was seen that, on average, only one out of 10 spots produced an 
unusually large or small peak ratio. Based on this observation, we used the following 
sampling procedure to improve the data reproducibility from spot to spot. All five 
spectra collected from the same sample were compared with each other. If any spectra 
produced a peak ratio larger or smaller than 30% of the average ratio, those spectra 
were discarded and only the remaining spectra were used to calculate the average 
peak ratio for that sample. Table 5.1 also lists the average peak ratios of each sample 
after we discarded two peaks (point 2 of sample 1 and point 5 of sample 2) having 
unusually large or small peak ratios. It was seen that the largest peak ratio difference 
among the six samples could be reduced to a level of less than 10%. Therefore, we 
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expect that when this method is used to measure the allele frequency of a pooling 
sample of more than five individuals, the error of the resulting frequency will be 
about 10%. However, if the pooling sample contains five individuals or less, this 
method can yield the precise allele frequency, as the smallest genotype frequency 
change is 33% from the 4/6 to 5/5 if the pooling sample contains five individuals. 
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Table 5.1 Experimentally determined peak ratios and calculated average peak ratios 
of 16/17mers. * SD = Standard Deviation 
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5.3.5 Analysis of Mini-sequencing Products 
This work was carried out with the primary aim of improving the overall 
detection sensitivity of the MALDI-TOF based genotyping methods. Therefore, we 
finally evaluated application of this method to the detection of mini-sequencing 
products. Mini-sequencing is a short sequencing reaction which only extends the 
sequencing primer by a few bases. The SNP site genotyped in this work was SNP888 
[Martin et al., 2000]. Two people were genotyped. One is Homozygous, while the 
other is C/T Heterozygous. In brief, genomic DNA was amplified by PCR, followed 
by purification with a size-exclusion column. The purified PCR products were then 
subjected to VSET mini-sequencing [Sun et al., 2000]. A sequencing primer is 
annealed to the target alleles immediately upstream of the SNP site, which is extended 
by one of the ddNTPs from one allele, then it is extended by the addition of one dNTP, 
and then terminated by a ddNTP from another allele. As a result, two extension 
products which differ by one base are produced from a heterozygous individual, while 
only one extension product is yielded from homozygous person. 50 or 100 fmol of the 
extension primer were used for mini-sequencing. A total of four identical 
mini-sequencing reactions were prepared for each concentration. Mini-sequencing 
products were subjected to purification with ZiptipTM (Millipore, MA, USA). The 
Oligonucleotides were eluted from the tip with 1μL of an aqueous solution containing 
20% of CH3CN. The mini-sequencing products were treated with the same tip three 
times to improve the oligonucleotide recovery efficiency. Thereafter, all recovered 
DNA solutions were combined and deposited on a sample well, followed by the 
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addition of matrix. 
Figure 5.4(a)-5.4(d) showed the results of genotyping of these two 
individuals using 100 and 50 fmol of the extension primer, respectively. Figure 5.4(a) 
and 5.4(b) were obtained from genotyping the C/T heterozygous individual, while 
Figure 5.4(c) and 5.4(d) were obtained from genotyping the homozygous individual. 
The peaks labeled P# (# =1 or 2) correspond to the extended primers. It was seen that 
the genotypes of all samples were correctly identified. In general, the signal quality 
and sample homogeneity from these mini-sequencing products were similar to those 
of the samples produced with 20 fmol of pure oligonucleotides. This suggests that the 
new procedure could indeed be used to analyze mini-sequencing products in a 
sensitive and accurate manner. The sensitivity achieved with this new procedure is 
about 10 times better than that achieved with currently used sample preparation 
methods, and is comparable with the sensitivity of fluorescence-based detection. 
Because of the lower amounts of extension primers used in mini-sequencing, less 
PCR products and DNA polymerase are required for mini-sequencing. 
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Figure 5.4 MALDI-TOF mass spectra obtained from genotyping two individuals ((a) 
and (b) C/T heterozygous; (c) and (d) C homozygous) using 100 and 50 fmol of the 
extension primers, respectively. The peaks labeled with * may be due to the products 
arising from the impurityies present in the mini-sequencing primers 
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5.4 Conclusions 
A new procedure for preparing MALDI samples on a hydrophobic surface 
was developed for the MALDI-TOF analysis of low-concentration oligonucleotides. 
This new procedure was simple, robust, and superior to the conventional sample 
preparation methods. It was shown that this procedure allowed the robust detection of 
as low as 0.01μM of oligonucleotides ranging from 15- to 30 mer. Moreover, the 
samples prepared by this procedure were more homogenous and therefore 
substantially reduced the need to search for ‘sweet’ spots. The increased shot-to-shot 
and sample-to-sample reproducibility also make it possible to perform 
high-throughput and quantitative analyses of DNA. It was shown that this procedure 
could reduce sample-to-sample peak ratio variation to the level of 10%, therefore 
allowing the accurate determination of the allele frequency of a pooling sample of at 
least five people. Importantly, we demonstrated that this procedure could improve the 
overall detection sensitivity of the MALDI-TOF-based genotyping method by about 
10-fold, evident by the robust detection of SNP888 using as little as 50 fmol of the 
extension primer. This detection sensitivity is comparable with that of the 
fluorescence-based detection method. 
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CHAPTER VI 
DETECTION OF MRS ALTERATIONS IN A LARGE BACKGROUND OF 
NORMAL DNA FOR SCREENING OF MSI-H CANCERS 
 
 
 
6.1 Introduction 
High-frequency microsatellite instability (MSI-H) is a form of genetic 
instability observed in virtually all tumors from tumors from patients with hereditary 
nonpolyposis colorectal cancer (HNPCC) and in a subset of various sporadic cancers. 
Its hallmark is extensive instability in simple repeat nucleotide sequences, including 
mononucleotide repeat sequences (MRS) and microsatellites [Boland et al., 1998]. 
MSI-H is most common in colorectal, gastric, and endometrial cancers [Markowitz et 
al., 1995; Halling et al., 1999; MacDonald et al., 2000; Alexander et al., 2001]. 
Colorectal cancer is the second deadliest cancer in the United States, and studies 
identified that about 15% of colorectal cancers are MSI-H, suggesting an annual 
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incidence in the United States of 20,000 to 26,000 MSI-H colorectal cancers each 
year [Alexander et al., 2001].  
Detection of colorectal cancer by the DNA analysis from stools is a 
promising screening method [Ahlquist et al., 2000 and 2002; Dong et al., 2001; 
Traverso et al., 2002a,b]. MRS markers are excellent indicators of MSI-H [Myeroff et 
al., 1995; Hoang et al., 1997; Grady et al., 1998; Zhou et al., 1998; Lacopetta et al., 
1999; Loukola et al., 1999; Jin et al., 2001; Loukola et al., 2001]. For example, 
BAT26 alterations were found in > 90% of MSI-H colon tumors, and 85% of MSI-H 
colon cancers harbor a mutation in transforming growth factor-β-RII (A)10 
(TGF-βRII (A)10) [Myeroff et al., 1995; Hoang et al., 1997; Zhou et al., 1998; 
Loukola et al., 2001]. Studies show that alterations of these markers are not present in 
normal tissues, suggesting that they are tumor specific [Grady et al., 1998; Lacopetta 
et al., 1999; Loukola et al., 1999; Jin et al., 2001]. Stools contain only a small 
percentage of mutated cells. Thus, molecular assays need to be highly sensitive such 
that altered DNA can be readily detected in a large background of wild-type DNA. 
Highly sensitive PCR-based methods are available for the point mutation detection 
[Orum et al., 1993; Jacobson et al., 1994; Lehman et al., 1996; Peter et al., 1997; Zirvi 
et al., 1999; Sun et al., 2002], but they are not suited for MRS analysis, as PCR itself 
can produce substantial slippage errors when a locus containing MRS is amplified. In 
other words, PCR can artificially yield mutant alleles even in the absence of mutant 
DNA, leading to false-positives. 
Ahlquist et al. reported on the use of a modified primer extension method for 
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the detection of BAT26 mutations in stool [Ahlquist et al., 2000 and 2002; Dong et al., 
2001]. However, primer extension methods may not work well for the detection of 
mutations in short MRS markers, such as TGF-β-RII (A)10, because polymerase 
slippage PCR products generated from the wild-type DNA can substantially overlap 
with the common (A)9 mutant. Recently, Vogelstein et al. developed an elegant digital 
PCR method [Vogelstein et al., 1999] and successfully employed this approach to 
detect mutant BAT26 alleles in fecal DNA [Traverso et al., 2002]. Digital PCR is 
sensitive, but the method requires analysis of a large number of subdivided samples 
each containing a single DNA molecule to screen each patient. 
We herein report an alternative detection strategy referred as probe clampling 
primer extension-PCR (PCPE-PCR) for the detection of MRS alternations in a large 
background of wild-type DNA. We demonstrated that PCPE-PCR can detect both 
mutated BAT26 and TGF-β-RII (A)10 markers in the presence of 500-fold excess of 
normal DNA, and that as few as three copies of mutant DNA could be detected. 
 
6.2 Methods and Materials 
Normal DNA was purchased from Sigma (St. Louis, MO). Mutant 
TGF-β-RII (A)10 DNA was extracted from cell line of HCL116, and mutant BAT26 
DNA was collected from cell line of HEC1A. The low-abundance mutant DNA 
samples were created by mixing mutant DNA with normal DNA. The abundance and 
number of mutant DNA in the created samples were estimated based on the number of 
mutant DNA in the original samples and dilution factors. The stool DNA samples 
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were extracted from stools of MSI-H colorectal cancer patients [Traverso et al., 2002]. 
In this work, a peptide nucleic acid probe of 5’-GGCTTTTTTTTTTCCT-3’ (Applied 
Biosystems, Foster City, CA) was used for TGF-β RII (A)10 assay, and an oligo probe 
(5’-GGTAAAAAAAAAAAAAAAAAAAAAAAAAAGGG-3’ ) was used for BAT26 
assay. The oligo probe was phosphorothioted at the first five positions of 5’ and 3’ 
ends to minimize the probe cleavage by DNA polymerases and was also 3’-end 
phosphorylated to prevent the probe itself from undergoing primer extension. 
For TGF-β RII (A)10, PCPE was carried out in 25μL using 3 μmol/L of the 
peptide nucleic acid probe, 0.01μmol/L of the extension primer 
(5’-Biotin-TGCACTCATCAGAGCTACAGG-3’), 0.1mmol/L of each 
deoxynucleotide triphosphates, 2mmol/L of MgCl2, 1x AmpliTaq Gold PCR buffer, 
and 0.5 unit of AmpliTaq Gold DNA polymerase (Applied Biosystems). After 
denaturation at 95  for 10 minutes, PCPE was done for 25 to 50 cycles consisting ℃ of 
30 seconds at 95 , 120 seconds at 58 , 60 seconds at 54 , and 60 seconds at 72 , ℃ ℃ ℃ ℃
with a final extension of 5 minutes at 72 . After PCPE, the formed single℃ -strand 
DNA fragments were captured using streptavidin-coated magnetic beads (Dynal 
Biotech, Lake Success, NY). Twentyfive microliters of extension products were 
mixed with equal volume magnetic beads in B&W buffer (10mmol/L Tris-HCl (pH 
7.5), 1mmol/L EDTA, 2.0mol/L NaCl ), and incubated at room temperature for 1 to 3 
hours. Thereafter, the supernatants were removed followed by washing the beads with 
200 μL of 0.1mol/L NaOH for 5 minutes, and twice by water.  
A similar procedure was used for BAT26 except for that PCPE was done in 
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25 to 50 cycles consisting of 30 seconds at 95 , 120 seconds at 68 , 60 sec℃ ℃ onds at 
62 , and 60 seconds at 72 , with a final extension of 5 minutes at 72 . The ℃ ℃ ℃
extension primer is 5’-Biotin-TGCAGTTTCATCACTGTCTGC-3’. 
The purified beads containing the single-strand DNA fragments served as 
templates of fluorescence-based PCR. The PCR mixture included 1x PCR buffer, 
0.2mmol/L of each deoxynucleotide triphosphates, 2mmol/L MgCl2, 0.1 μmol/L of 
the forward and reverse primers, and 0.5 unit of TaqGold DNA polymerase, 
respectively. After denaturation at 95  for 10 minutes, PCR (25μL) was d℃ one for 42 
cycles consisting of 30 seconds at 95 , 30 seconds at 54 , and 30 seconds at 72 , ℃ ℃ ℃
with a final extension of 5 minutes at 72  for TGF℃ -β RII (A)10 and BAT26. The 
fluorescence-labeled PCR products were size analyzed using a CEQ8000 sequencer 
(Beckman Coulter, Fullerton California). The forward and reverse primers used were 
5’-GAAGATGCTTCTCCAA-3’ and 5’-dye(D4)-ATCAGAGCTACAGGAACAC-3’ 
for TGF-β-RII (A)10, 5’-dye(D4)-ATTGGATATTGCAGCAGTC-3’ and 
5’-AACCAATCAACATTTTTAACCC-3’ for BAT 26, respectively. 
Fecal DNA samples from individuals having MSI-H colon cancers were the 
kind gift of Dr. Bert Vogelstein (John Hopkins University) and corresponded to 
samples previously employed in studies published by Dr. Vogelstein’s laboratory. 
 
6.3 Results and Discussion 
6.3.1 Principle of PCPE-PCR 
A PCPE-PCR assay consists of five steps. First, DNA is extracted from a 
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clinical sample, such as stools. Second, the DNA samples containing both mutant and 
wild-type alleles are subject to PCPE that preferentially produces extension products 
of mutant DNA. Third, the extension products are extracted, leading to enrichment of 
mutant DNA. Fourth, PCR is done using the extracted extension products as templates. 
Finally, PCR products are analyzed using DNA fragment analysis or other methods to 
reveal the mutations. Figure 6.1 shows a schematic representation of detecting mutant 
DNA (A9) in a large background of normal DNA (A)10 by PCPE-PCR.  
The second and third steps are key to PCPE-PCR. As shown in Figure 6.1, 
the PCPE system has an extension primer and a blocking probe, both of which are 
complementary to the same strand of the wild-type sequence. The blocking probe is 
complementary to a wild-type sequence containing MRS and designed in such a way 
that probe-DNA duplexes are more stable than extension primer-DNA duplexes when 
DNA is wild-type but less stable than extension primer-DNA duplexes if DNA is 
mutated. As a result, this blocking probe can tightly bond to wild-type DNA, 
preventing read-through by polymerases (elongation arrest); thus, shorter extension 
products that do not contain the MRS sequence are formed (note that they will not be 
amplified by the following PCR as one of the PCR primers will not cover them). In 
contrast, when DNA is mutated, this blocking probe would no longer bind to the 
targeted mutation site; thereby, primer elongation is initiated by polymerases, and 
long extension products containing the altered MRS sequence are formed. In this 
method, we use solid-phase extraction to extract the extension products. A biotin is 
incorporated to the extension primer; therefore, the formed extension products are 
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consequently biotinylated as well. The extension products are isolated using a 
biotin-streptavidin affinity extraction procedure, leading to enrichment of mutant 
DNA. Thereafter, we use the extracted extension products as PCR templates, and the 
mutation is revealed by analyzing the PCR products. 
In this study, we used the TGF-β-RII (A)10 and BAT26 markers as examples 
to show the detection of mutations in both short and long MRS markers by this new 
technology, respectively. 
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Figure 6.1 Schematic illustration of the PCPE-PCR principle of detecting mutant 
DNA (A9) in the presence of a large background of normal DNA (A10). 
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6.3.2 Detection of Mutations in TGF-β RII (A) 10 
We first used PCPE-PCR to detect mutations of short MRS marker, which 
contain 12 or less repeats, and they are often altered by one or two bases. Because of 
PCR slippage, it can be challenging to detect these mutations in the presence of 
excessive wild-type alleles. For example, 10% to 30% of the PCR products amplified 
from the normal TGF-β-RII (A)10 allele can be shortened A9 alleles, making it 
challenging for  conventional methods to detect the legitimate presence of the mutant 
A9 allele if the abundance of mutant DNA is low. However, the detection of this 
marker was readily achieved by PCPE-PCR. 
Figure 6.2A shows the PCR product distribution obtained using primer 
extension but without blocking probe. The sample contained only wild-type DNA. It 
was seen that this distribution was identical to that generated from PCR without 
primer extension, establishing the fact that the sequence of the DNA molecule 
produced from primer extension truly reflects that of genomic DNA. The A9 peak 
seen in Figure 6.2A was due to PCR slippage, and its intensity was generally <50% 
of the A10 intensity. Because of this fact, we can use the peak intensity ratio of A9 to 
A10 to determine whether mutant DNA is present. It was found that a ratio of 0.8 is a 
good threshold to robustly distinguish the legitimate presence of the A9 allele from 
the artificial production of this allele by PCR slippage. In other words, we called the 
legitimate presence of the mutant A9 allele in the sample if the ratio is 0.8. Otherwise, 
the absence of mutant DNA would be called.  
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Figure 6.2 TGF-β-RII (A)10 spectra obtained from different conditions. It is noted 
that: (a) PE-PCR denotes the use of primer extension (without the blocking probe) 
followed by PCR; (b) the percentage indicates the abundance of mutant DNA in the 
sample; (c) the peak A9 corresponds to mutant DNA, whereas the peak A10 
corresponds to wild-type DNA. 
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Figure 6.2B shows the result of detecting 1% (0.5 ng) of mutant DNA in 50 
ng of normal DNA without the blocking probe, where no mutant DNA was observed. 
In contrast, Figure 6.2C displays the result obtained from the same sample but with 
the blocking probe, where the A9 peak became stronger than the A10 peak, indicating 
the legitimate presence of mutant DNA in the sample assayed. Figure 6.2D displays 
the result of detecting 0.1 ng (0.2%) of mutant DNA in 50 ng of normal DNA, where 
the A9 peak was still stronger, establishing that PCPE-PCR could detect 0.2% of 
mutant TGF-h-RII (A)10. The amount of human DNA extracted from a clinical 
specimen may vary from patient to patient; thus, the assay must have a good dynamic 
range. Figure 6.2E displays the detection of mutant DNA (0.2%) in the presence of 1 
µg of normal DNA, indicating that PCPE-PCR works well in a large dynamic range. 
It should be noted that the specificity of this assay is good as shown by assaying pure 
wild-type DNA (Figure 6.2F), where the A9 peak was <50% of the A10 peak, 
correctly indicating the absence of mutant DNA. . 
 
6.3.3 Detection of Mutations in BAT26 
We next used PCPE-PCR to detect mutations in large MRS markers. These 
makers generally contain 20 repeats or more and typically contract by multiple bases. 
BAT26, one of the most wildly used markers for MSI-H colon cancer, was examined. 
BAT26 typically contracts by 10 bases or more in MSI-H colorectal cancer but 
contracts less in adenoma. The data shown here were based on the detection of mutant 
BAT26 from cell line HEC1A, in which one allele contains about 14As (large 
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deletion), whereas another has 20As (small deletion). The use of this mutant cell line 
allowed us to evaluate the performance of PCPE-PCR in the detection of both small 
and large deletions under the same assaying condition. Figure 6.3A and 6.3B shows 
the PCR product distribution of both pure normal and mutant BAT26 DNA, 
respectively. The numbers shown in these spectra specify the size of the 
corresponding PCR products. The peaks clustering around the positions of 86, 80, and 
74 corresponded to the PCR products arising from wild-type BAT26, small deletion in 
BAT26, and large deletion in BAT26, respectively. The formation of multiple peaks 
resulted from PCR slippage. As seen from Figure 6.3A, when there was no mutant 
DNA, the PCR products of wild-type DNA cluster around peak 86, and the peak 
intensity of smaller PCR products generally decrease with a decrease in DNA size. 
For example, peak 80 is weaker than peak 81. However, when mutant DNA was 
present, the PCR product distribution changed substantially as shown in Figure 6.3B. 
In general, the PCR products of BAT26 with large deletion do not substantially 
overlap with those of normal DNA, allowing the determination of mutant DNA based 
on the DNA fragment size. For example, the appearance of peaks around position 74 
is indicative of large deletion in BAT26. Although PCR products of BAT26 with small 
deletion do overlap with those of wild-type DNA, the peak intensity pattern becomes 
altered due to overlapping. For example, peak 79 is stronger than peak 81 in Figure 
3B. Thus, we were able to determine whether small deletion in BAT26 was 
legitimately present based on the resulting changes in the peak intensity pattern. 
 
 127
  
 
 
Figure 6.3 BAT26 spectra obtained from different conditions and samples. It is noted 
that: (a) PE-PCR denotes the use of primer extension (without the blocking probe) 
followed by PCR; (b) the percentage indicates the abundance of mutant DNA in the 
sample; and (c) the numbers of 86, 80, 79, and 74 specify the size of the 
corresponding PCR products. 
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Figure 6.3C shows the detection of 1% (0.5 ng) of mutant DNA in 50 ng of 
wild-type DNA without the blocking probe, where no mutant DNA was observed. 
Figure 3D displays the result obtained form the same sample but with the blocking 
probe, where new peaks appeared around the peak position of 74, indicating the 
presence of large deletion in BAT26. In addition, peaks 79 and 80 became stronger 
than peak 81, suggesting the presence of small deletion in BAT26. Figure 6.3E 
displays the result of detecting 0.1 ng of mutant DNA (0.2%) in 50 ng of normal DNA, 
where the peaks clustering around 74 were seen, revealing the presence of large 
deletion in BAT26. Moreover, peak 79 was higher than peak 81, indicating the 
presence of small deletion in BAT26. Figure 6.3F was obtained using pure wild-type 
DNA, where neither new peaks nor a change in the peak intensity pattern were 
observed, indicating the absence of mutant DNA. It is noted that the above 
experiments were repeated at least twice, and the consistent results were obtained. 
Several studies established that the abundance of mutant DNA in stools was 
generally >0.5% [Dong et al., 2001; Traverso et al., 2002a,b]; thus, an assay with such 
a sensitivity should be adequate to detect mutant BAT26 from stools [Traverso et al., 
2002a,b]. Although the BAT26 assay is generally more sensitive to detecting large 
deletion in BAT 26, it is capable of detecting 0.2% of mutant BAT26 that was deleted 
by six bases, suggesting that the PCPE-PCR–based BAT26 assay could detect both 
small and large deletion in BAT26 in a sensitive manner. This feature is important to 
screening as the size of deletion in BAT26 varies among patients. 
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Figure 6.4 Fragment analysis spectrum obtained from the PCPE-PCR analysis of 
three copies of both large deletion and small deletion BAT26 in the presence of 600 
copies wild-type DNA. 
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Because mutant DNA extracted from stools could be scanty [Dong et al., 
2001; Traverso et al., 2002a,b], we also determined the lowest copy of the mutant 
BAT26 molecules that could be detected in the presence of a 200-fold excessive 
amount of wild-type DNA. As seen from Figure 6.4, three copies of both 12- and 
6-base deleted BAT26 were detected in the presence of 600 copies of normal DNA 
using our BAT26 assay. It was reported that at least 4,000 copies of human DNA 
could be extracted from 10 g of stools, yielding at least 20 copies of mutant DNA 
[Dong et al., 2001; Traverso et al., 2002a,b]. Thus, the BAT26 assay is sufficiently 
sensitive for fecal DNA testing.  
 
6.3.4 Detection of Mutations from Fecal DNA 
We finally tested the BAT26 assay in a set of six fecal DNA samples 
extracted from stool samples collected from MSI-H colorectal cancer patients to 
determine whether this assay can detect MSI-H colorectal tumors. Stool DNA was 
extracted and purified as described previously [Traverso et al., 2002]. Because the 
samples were originally extracted for digital PCR, the total number of human DNA 
molecules in them is low. Figure 6.5 shows the result of detecting the BAT26 
mutations from one of the stool DNA samples using PCPE-PCR, where the total 
amount of stool DNA used was about 120 copies. The peaks clustering around the 
peak position 72 indicated the presence of mutated BAT26, thus revealing that this 
patient has an MSI-H colorectal tumor. Mutated BAT26 molecules were similarly 
successfully detected from three of the other assayed fecal DNA samples. However, 
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two of the six fecal DNA samples from MSI-H patients tested negative for BAT-26 
because of failure of observing PCR products. During the course of this work, we 
found that the assay would become less robust when mutant DNA molecules were 
less than three copies. This is because robust isolation of extension products became 
challenging if fewer biotinylated molecules were formed. Because the total number of 
human DNA in the samples are 120 copies, we suspect that in these two negative 
samples, the copy number of mutant DNA may be <3, which is the minimum level 
required for PCPE-PCR to detect the mutated BAT26 molecules. 
The test is clearly very sensitive; however, the specificity has yet to be 
completely determined with fecal DNA samples and will need to be further studied in 
a large number of samples from patients. 
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Figure 6.5 Fragment analysis spectrum obtained from the PCPE-PCR analysis of the 
BAT26 mutation in a stool DNA sample collected from a MSI-H colorectal cancer 
patient. It is noted that the peaks around 72 correspond to mutated BAT26, whereas 
the peaks around 86 correspond to wild-type DNA. 
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6.4 Conclusion 
PCPE-PCR offers several unique features. First, PCPE-PCR is sensitive. 
Second, the same PCPE-PCR assay can be used to detect both large and small 
deletions. Third, the PCPE-PCR assay uses primer extension as pre-amplification to 
increase template copies, allowing the detection of low copies of mutant DNA. This 
feature is particularly useful in analysis of fecal-derived DNA, where mutant DNA 
may be scarce. Finally, PCPE-PCR is simple and amendable to a cost-effective and 
high-throughput operation.  
Clearly, the primary application of the PCPE-PCR assay is for noninvasive 
screening of MSI-H cancers. In the case of colorectal cancer, a combination of 
sigmoidoscopy and stool analysis has been suggested to be a potentially cost-effective 
alternative to colonoscopy [Traverso et al., 2002]. Sigmoidoscopy inspects the distal 
colon, whereas PCPE-PCR detects MSI-H tumors, which often occur in the proximal 
colon. Hence, PCPE-PCR can be a part of a group of methods for screening of 
colorectal cancers. It should be noted that the PCPE-PCR strategy reported here is a 
general strategy and thus can also be used to design assays for the detection of other 
important MRS markers, including BAT25 and short MRS in BAX [Lacopetta et al., 
1999]. If this method is used to detect a marker such as BAT 26, which is 
polymorphic, it is necessary to test germ line DNA to distinguish the legitimate 
mutations from polymorphism. In addition, PCPE-PCR can detect other DNA 
mutations. In the case of point mutations, our preliminary work indicated that 
PCPE-PCR could detect p53 mutations in a large background of normal DNA. Hence, 
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PCPE-PCR could potentially serve as a generally applicable method for the detection 
of various DNA alterations in a large background of normal DNA. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 135
Reference 
 
L.A. Aaltonen, P. Peltomaki, F.S. Leach, et al., “Clues to the pathogenesis of familial 
colorectal cancer”, Science, 260:812-816 (1993) 
 
D.A. Ahlquist, J.E. Skoletsky, K.A. Boynton, et al., “Colorectal cancer screening by 
detection of altered human DNA in stool: feasibility of a multitarget assay panel”, 
Gastroenterology, 119:1219-1227 (2000) 
 
D.A. Ahlquist and A.P. Shuber, “Stool screening for colorectal cancer: evolution from 
occult blood to molecular markers”, Clin. Chim. Acta., 315:157-168 (2002) 
 
J. Alexander, T. Watanabe, T.T. Wu, et al., “Histopathological identification of colon 
cancer with microsatellite instability”, Am. J. Pathol., 158:527-535 (2001) 
 
T. Blondal, B.G. Waage, S.V. Smarason, et al., “A novel MALDI-TOF based 
methodology for genotyping single nucleotide polymorphisms”, Nucleic Acids Res., 
31:e155 (2003) 
 
C.R. Boland, S.N. Thibodeau, S.R. Hamilton, et al., “A National Cancer Institute 
Workshop on Microsatellite Instability for cancer detection and familial predisposition: 
development of international criteria for the determination of microsatellite instability 
 136
in colorectal cancer”, Cancer Res., 58:5248-5257 (1998) 
 
A. Braun, D.P. Little and H. Koster, “Detecting CFTR gene mutations using primer 
oligo base extension and mass spectrometry”, Clin. Chem., 43:1151−1158 (1997) 
 
A. Braun, D.P. Little, D. Reuter, et al., “Improved analysis of microsatellites using 
mass spectrometry”, Genomics, 46:18−23 (1997) 
 
A.J. Brookes, “The essence of SNPs”, Gene, 234:177-186 (1999) 
 
J.W.F. Catto, G. Xinarianos, J.L. Burton, et al., “Differential expression of hMLH1 
and hMSH2 is related to bladder cancer grade, stage and prognosis, but not 
microsatellite instability”, Int J Cancer, 105(4):484-490 (2003) 
 
J.W.F. Catto, M. Meuth and F.C. Hamdy, “Genetic instability and transitional cell 
carcinoma of the bladder”, BJU International, 93(1):19-24 (2004) 
 
X. Chen, Z. Fei, L.M. Smith, et al., “Stable-isotope-assisted MALDI-TOF mass 
spectrometry for accurate determination of nucleotide compositions of PCR products”, 
Anal. Chem., 71:3118-3128 (1999) 
 
F.S. Collins, M. Morgan and A. Patrinos, “The human genome project: lessons from 
 137
large-scale biology”, Science, 300:286-290 (2003) 
 
D.N. Cooper, B.A. Smith, H.J. Cooke, et al., “An estimate of unique DNA sequence 
heterozygosity in the human genome”, Hum. Genet., 69:201-205 (1985) 
 
M. Danjoux, R. Guimbaud, T.A. Saati, et al., “Contribution of microdissection for the 
detection of microsatellite instability in colorectal cancer”, Human Pathology, 37: 
361-368 (2006) 
 
V. Deschoolmeester, M. Baay, and W. Wuyts, “Comparison of Three Commonly Used 
PCR-Based Techniques to Analyze MSI Status in Sporadic Colorectal Cancer”, 
Journal of Clinical Laboratory Analysis, 20:52-61 (2006) 
 
C. Dib, S. Faure, C. Fizames, et al., “A comprehensive genetic map of the human 
genome based on 5264 microsatellites”, Nature, 380:152-154 (1996) 
 
W. Dietmaier and F. Hofstädter, “Detection of Microsatellite Instability by Real Time 
PCR and Hybridization Probe Melting Point Analysis”, Lab Invest., 81:1453-1456 
(2001) 
 
S.M. Dong, G. Traverso, C. Johnson, et al., “Detecting colorectal cancer in stool with 
the use of multiple genetic targets”, J. Natl. Cancer Inst., 93:858-865 (2001) 
 138
Z. Fei, T. Ono and L.M. Smith, “MALDI-TOF mass spectrometric typing of single 
nucleotide polymorphisms with mass-tagged ddNTPs”, Nucleic Acids Research, 
26(11):2827–2828 (1998) 
 
R. Fishel, “Signaling mismatch repair in cancer”, Nat Med., 5:1239-1241 (1999) 
 
D. Fu, K. Tang, A. Braun, et al., “Sequencing exons 5 to 8 of the p53 gene by 
MALDI-TOF mass spectrometry”, Nat. Biotechnol., 16(4):381-384 (1998) 
 
I. Gonzalez-Garcia, V. Moreno, M. Navarro, et al., “Standardized approach for 
microsatellite instability detection in colorectal carcinomas”, J Natl Cancer Inst., 
92:544-549 (2000) 
 
W.M. Grady, A. Rajput, L. Myeroff, et al., “Mutation of the type II transforming 
growth factor-h receptor is coincident with the transformation of human colon 
adenomas to malignant carcinomas”, Cancer Res. 58:3101-3104 (1998) 
 
T.J. Griffin, J.G. Hall, J.R. Prudent, et al., “Direct genetic analysis by matrix-assisted 
laser desorption/ionization mass spectrometry”, Proc. Natl. Acad. Sci., 96:6301-6306 
(1999) 
 
I.G. Gut, W.A. Jeffery, D.J.C. Pappin, et al., “Analysis of DNA by ‘Charge Tagging’ 
 139
and matrix-assisted laser desorption/ionization mass spectrometry”, Rapid Commun. 
Mass Sprectrom., 11: 43-50 (1997) 
 
G. Gyapay, F. Ginot, S. Nguyen, et al., “Genotyping Procedures in Linkage Mapping”, 
Methods, 9:91-97 (1996) 
 
L.A. Haff and I.P. Smirnov, “Single-Nucleotide Polymorphism Identification Assays 
Using a Thermostable DNA Polymerase and Delayed Extraction MALDI-TOF 
Mass Spectrometry”, Genome Res., 7:378-388 (1997) 
 
L.A. Haff and I.P. Smirnov, “Multiplex genotyping of PCR products with 
MassTag-labeled primers”, Nucleic Acids Res., 25:3749-3750 (1997) 
 
K.C. Halling, J. Harper, C.A. Moskaluk, et al., “Origin of microsatellite instability in 
gastric cancer”, Am. J. Pathol., 155:205-211 (1999) 
 
A.M. Haydon and J.R. Jass, “Emerging pathways in colorectal-cancer development”, 
Lancet Oncol., 3:83-88 (2002) 
 
C.M. Hearne, S. Ghosh and J.A. Todd, “Microsatellites for linkage analysis of genetic 
traits”, Trends Genet., 8:288-294 (1992) 
 
 140
G..S. Higgins, D.P. Little, H. Koster, “Competitive oligonucleotide single base 
extension combined with mass spectrometric detection for mutation screening”, 
Biotechniques, 23:710−714 (1997) 
 
J.M. Hoang, P.H. Cottu, B. Thuille, et al., “BAT-26, an indicator of the replication 
error phenotype in colorectal cancers and cell lines”, Cancer Res., 57:300-303 (1997) 
 
K.C. Hung, H. Rashidzadeh, Y. Wang, et al., “Use of Paraffin Wax Film in 
MALDI-TOF Analysis of DNA”, Anal. Chem., 70:3088-3093 (1998) 
 
Y. Ionov, M.A. Peinado, S. Malkhosyan, et al., “Ubiquitous somatic mutations in 
simple repeated sequences reveal a new mechanism for colonic carcinogenesis”, 
Nature, 363:558-561 (1993) 
 
D.R. Jacobson and N.E. Mills, “A highly sensitive assay for mutation ras genes and its 
application to the study of presentation and relapse genotypes in acute leukemia”, 
Oncogene, 9:553-563 (1994) 
 
Z. Jin, G. Tamura, M. Satoh, et al., “Absence of BAT-26 instability in gastric intestinal 
metaplasia”, Pathol. Int., 51:473-475 (2001) 
I.J. Kim, Y. Shin, H.C. Kang, et al., “Robust microsatellite instability (MSI) analysis 
by denaturing high-performance liquid chromatography (DHPLC)”, J Hum Genet., 
 141
48:525-530 (2003) 
 
S. Kim, J.R. Edwards, L. Deng, et al., “Solid phase capturable dideoxynucleotides for 
multiplex genotyping using mass spectrometry”, Nucleic Acids Res., 30:e85 (2002) 
 
B.J. Lacopetta, R. Soong, A.K. House, et al., “Gastric carcinomas with microsatellite 
instability: clinical features and mutations to the TGF-b type II receptor, IGF-II 
receptor and BAX genes”, J. Pathol. 187:428-432 (1999) 
 
S. Le Hellard, S.J. Ballereau, P.M. Visscher, et al., “SNP genotyping on pooled DNAs: 
comparison of genotyping technologies and a semi automated method for data storage 
and analysis”, Nucleic Acids Res., 30:e74 (2002) 
 
P. Lecchi and L.K. Pannell, “6-Aza-2-thio-thymine: a matrix for MALDI spectra of 
oligonucleotides”, J. Am. Soc. Mass Spectrum., 6:1276-1277 (1995) 
 
T.A. Lehman, F. Scott, M. Seddon, et al., “Detection of K-ras oncogene mutations by 
polymerase chain reaction based ligase chain reaction”, Anal. Biochem., 239:153-159 
(1996) 
 
J. Leushner and N.H. Chiu, “Automated mass spectrometry: a revolutionary 
technology for clinical diagnostics”, Mol. Diagn., 5:341-348 (2000) 
 142
 J. Li, J.M. Butler, Y. Tan, et al., “Single nucleotide polymorphism determination using 
primer extension and time-of-flight mass spectrometry”, Electrophoresis, 
20:1258-1265 (1999) 
 
M. Litt and J.A. Luty, “A hypervariable microsatellite revealed by in vitro 
amplification of a dinucleotide repeat within the cardiac muscle actin gene”, Am. J. 
Hum. Genet., 44:397-401 (1989) 
 
D.P. Little, A. Braun, B. Darnhofer-Demar, et al., “Apolipoprotein E polymorphism 
identification using temperature cycled primer oligo base exten-sion and mass 
spectrometry”, Eur. J. Clin. Chem. Clin. Biochem., 35:545−548 (1997) 
 
D.P. Little, A. Braun, B. Darnhofer-Demar, et al., “Rapid detection of RET 
proto-oncogene codon 634 mutations using mass spectrometry”, J. Mol. Med., 
75:745−750 (1997) 
 
D.P. Little, A. Braun, M.J. O’Donnell, et al., “Mass spectrometry from miniaturized 
arrays for full comparative DNA analysis”, Nat. Med., 3: 1413-1416 (1997) 
 
D.P. Little, T.J. Cornish, M.J. O’Donnell, et al., “MALDI on a Chip: Analysis of 
Arrays of Low-Femtomole to Subfemtomole Quantities of Synthetic Oligonucleotides 
 143
and DNA Diagnostic Products Dispensed by a Piezoelectric Pipet”, Anal. Chem., 
69:4540-4546 (1997) 
 
A. Loukola, R. Salovaara, P. Kristo, et al., “Microsatellite instability in adenomas as 
amarker for hereditary nonpolyposis colorectal cancer”, Am. J. Pathol., 155: 
1849-1853 (1999) 
 
A. Loukola, K. Eklin, P. Laiho, et al., “Microsatellite marker analysis in screening for 
hereditary nonpolyposis colorectal cancer (HNPCC)”, Cancer Res., 61:4545-4549 
(2001) 
 
N.D. MacDonald, H.B. Salvesen, A. Ryan, et al., “Frequency and prognostic impact 
of microsatellite instability in a large population-based study of endometrial 
carcinomas”, Cancer Res., 60:1750-1752 (2000) 
 
M. Maekawa, K. Sugano, H. Kashiwabara, et al., “DNA Methylation Analysis Using 
Bisulfite Treatment and PCR–Single-Strand Conformation Polymorphism in 
Colorectal Cancer Showing Microsatellite Instability”, Biochemical and Biophysical 
Research Communications, 262:671-676 (1999) 
 
L. Mao, D.J. Lee, M.S. Tockman et al., “Microsatellite alterations as clonal markers 
for the detection of human cancer”, Proc Natl Acad Sci., 91:9871-9875 (1994) 
 144
L. Mao, M.P. Schoenberg, M. Scicchitano et al., “Molecular detection of primary 
bladder cancer by microsatellite analysis”, Science, 271:659-662 (1996) 
 
S.J. Markowitz, J. Wang, L. Myeroff, et al., “Inactivation of the type II TGF-receptor 
in colon cancer cells with microsatellite instability”, Science, 268:1336-1338 (1995) 
 
E.R. Martin, E. Lai, J. Gilbert, et al., “SNPing Away at Complex Diseases: Analysis of 
Single-Nucleotide Polymorphisms around APOE in Alzheimer Disease”Am. J. Hum. 
Genet., 67:383-394 (2000) 
 
T. Miliotis, S. Kjellstrom, P. Onnerfjord, et al., “Protein identification platform 
utilizing micro dispensing technology interfaced to matrix-assisted laser desorption 
ionization time-of-flight mass spectrometry”, Chromatogr. A, 886:99-110 (2000) 
 
H. Murata, N.H. Khattar, Y. Kang, et al., “Genetic and epigenetic modification of 
mismatch repair genes hMSH2 and hMLH1 in sporadic breast cancer with 
microsatellite instability”, Oncogene, 21(37):5696-5703 (2002) 
 
L. Myeroff, R. Parsons, S.J. Kim, et al., “A transforming growth factor h receptor type 
II gene mutation common in colon and gastric but rare in endometrial cancers with 
microsatellite instability”, Cancer Res., 55:5545-5547 (1995) 
 
 145
P. Nollau and C. Wagenera, “Methods for detection of point mutations: performance 
and quality assessment, on behalf of the IFCC Scientific Division and Committee on 
Molecular BiologyTechniques”, Clin. Chem., 43:1114-1128 (1997) 
 
E. Nordhoff, A. Ingendoh, R. Cramer, et al., “Matrix-assisted laser 
desorption/ionization mass spectrometry of nucleic acids with wavelengths in the 
ultraviolet and infrared”, Rapid Commun. Mass Spectrom., 6:771-776 (1992) 
 
S. Oda, E. Oki, Y. Maehara, et al., “Precise assessment of microsatellite instability 
using high resolution fluorescent microsatellite analysis”, Nucleic Acids Res.,  
25:3415-3420 (1997) 
 
H. Orum, P.E. Nielsen, M. Egholm, et al., “Single base pairmutation analysis by PNA 
directed PCR clamping”, Nucleic Acids Res., 21:5332-5336 (1993) 
 
P. Peltomaki, R.A. Lothe, L.A. Aaltonen, et al., “Microsatellite instability is 
associated with tumors that characterize the hereditary nonpolyposis colorectal 
carcinoma syndrome”, Cancer Res., 53:5853-5855 (1993) 
 
U. Pieles, W. Zürcher, M. Schär, et al., “Matrix-assisted laser desorption/ionization 
time-of-flight mass spectrometry: a powerful tool for the mass and sequence analysis 
of natural and modified oligonucleotides”, Nucleic Acids Res., 21:3191-3196 (1993) 
 146
M.A. Rodriguez-Bigas, C.R Boland, S.R. Hamilton, et al., “A national cancer institute 
workshop on hereditary nonpoliposis colorectal cancer institute workshop on 
hereditary nonpoliposis colorectal cancer syndrome: meeting highlights and Bethesda 
guidelines”, J Natl Cancer Inst., 89:1758-1762 (1997) 
 
P. Ross, L. Hall, I.P. Smirnov, et al., “High level multiplex genotyping by 
MALDI-TOF mass spectrometry”, Nat Biotechnol., 16:1347–1351 (1998) 
 
R. Sachidanandam, D. Weissman, S.C. Schmidt, et al., “A map of human genome 
sequence variation containing 1.42 million single nucleotide polymorphisms”, Nature, 
409:928-933 (2001) 
 
K. Samara, M. Zervou, N.M. Siafakas, et al., “Microsatellite DNA instability in 
benign lung diseases”, Respiratory Medicine, 100:202-211 (2006) 
 
S. Sauer, D. Lechner, K. Berlin, et al., “A novel procedure for efficient genotyping of 
single nucleotide polymorphisms”, Nucleic Acids Res., 28:e13 (2000) 
 
S. Sauer, D. Lechner, K. Berlin, et al., “Full flexibility genotyping of single nucleotide 
polymorphisms by the GOOD assay”, Nucleic Acids Res., 28:e100 (2000) 
 
J.J. Scarisbrick, T.J. Mitchell, E. Calonje, et al., “Microsatellite Instability Is 
 147
Associated with Hypermethylation of the hMLH1 Gene and Reduced Gene 
Expression in Mycosis Fungoides”, Journal of Investigative Dermatology, 121: 
894-901 (2003) 
 
J. Schlegel, T. Vogt, K. Munkel, et al., “DNA fingerprinting of mammalian cell lines 
using nonradioactive arbitrarily primed PCR (AP-PCR)”, Biotechniques, 20:178-180 
(1996) 
 
M. Schuerenberg, C. Luebbert, H. Eickhoff, et al., “Prestructured MALDI-MS 
Sample Supports”, Anal. Chem., 72:3436-3442 (2000) 
 
S.P. Siah, D.M. Quinn, G.D. Bennett, et al., “Microsatellite instability markers in 
breast cancer: A review and study showing MSI was not detected at ‘BAT 25’ and 
‘BAT 26’ microsatellite markers in early-onset breast cancer”, Breast Cancer Research 
and Treatment, 60:135-142 (2000) 
 
M. Strand, T.A. Prolla, R.M. Liskay, et al., “Destabilization of tracts of simple 
repetitive DNA in yeast by mutations affecting DNA mismatch repair”, Nature, 
365:274-276 (1993) 
 
X. Sun, H. Ding, K. Hung, et al. “A new MALDI-TOF based mini sequencing assay 
for genotyping of SNPS”, Nucleic Acids Res., 28: e68 (2000) 
 148
X. Sun, K. Hung, L. Wu, et al., “Detection of tumor mutations in the presence of 
excess amounts of normal DNA”, Nat. Biotechnol. 20:186-189 (2002) 
 
A.C. Syvänen, K. Aalto-Setala, L. Harju, et al., “A primer-guided nucleotide 
incorporation assay in the genotyping of apolipoprotein E”, Genomics, 8:684-692 
(1990) 
 
K. Tang, D.J. Fu, S. Kotter, et al., “Matrix-assisted laser desorption/ionization mass 
spectrometry of immobilized duplex DNA probes”, Nucleic Acids Res., 23: 
3126-3131 (1995) 
 
S.N. Thibodeau, G. Bren, and D. Schaid, “Microsatellite instability in cancer of the 
proximal colon”, Science, 260:816-819 (1993) 
 
J. Tost and I.G. Gut, “Genotyping single nucleotide polymorphisms by MALDI mass 
spectrometry in clinical applications”, Clinical Biochemistry, 38:335-350 (2005) 
 
G. Traverso, A. Shuber, L. Olsson, et al., “Detection of proximal colorectal cancers 
through analysis of faecal DNA”, Lancet, 359:403-404 (2002) 
 
G. Traverso, A. Shuber, B. Levin, et al., “Detection of APC mutations in fecal DNA 
from patients with colorectal tumors”, N. Engl. J. Med., 346:311-320 (2002) 
 149
A. Umar, C.R. Boland, J. Terdiman, et al., “Revised bethesda Guidelines for 
Hereditary Nonpolyposis Colorectal Cancer (Lynch Syndrome) and Microsatellite 
Instability”, J Natl Cancer Inst., 96:261-267 (2004) 
 
B. Vogelstein and W. Kinzler, “Digital PCR”, Proc. Natl. Acad. Sci. USA, 
96:9236-9241 (1999) 
 
J.L. Weber and P.E. May, “Abundant class of human DNA polymorphisms which can 
be typed using the polymerase chain reaction”, Am. J. Hum. Genet., 44:388-396 
(1989). 
 
T. Wenzel, T. Elssner, K. Fahr, et al., “Genosnip: SNP genotyping by MALDI-TOF 
MS using photocleavable oligonucleotides”, Nucleotides, Nucleotides and Nucleic 
Acids, 22:1579-1581 (2003) 
 
P. Wild, R. Knuechel, W. Dietmaier, et al., “Laser microdissection and microsatellite 
analyses of breast cancer reveal a high degree of tumor heterogeneity”, Pathobiology, 
68(4–5):180-190 (2000) 
 
T. Yamada, T. Koyama, S. Ohwada, et al., “Frameshift mutations in the MBD4/MED1 
gene in primary gastric cancer with high-frequency microsatellite instability”, Cancer 
Letters, 181:115-120 (2002) 
 150
 151
X.P. Zhou, J.M. Hoang, Y.J. Li, et al., “Determination of the replication error 
phenotype in human tumors without the requirement formatching normal DNA by 
analysis of mononucleotide repeat microsatellites”, Genes Chromosomes Cancer, 
21:101-107 (1998) 
 
M. Zirvi, T. Nakayama, G. Newman, et al., “Ligasebased detection ofmononucleotide 
repeat sequences”, Nucleic Acids Res., 27:e40-40 (1999) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
